0000849636 2023-01-01 2023-06-30 0000849636 2023-08-18 0000849636 2023-06-30 0000849636 2022-12-31 0000849636 RSPI:SYCorporationMember 2023-06-30 0000849636 RSPI:SYCorporationMember 2022-12-31 0000849636 srt:OfficerMember 2023-06-30 0000849636 srt:OfficerMember 2022-12-31 0000849636 RSPI:FormerOfficerMember 2023-06-30 0000849636 RSPI:FormerOfficerMember 2022-12-31 0000849636 RSPI:SeriesBConvertiblePreferredStockMember 2023-06-30 0000849636 RSPI:SeriesBConvertiblePreferredStockMember 2022-12-31 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember 2023-06-30 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember 2022-12-31 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember 2023-06-30 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember 2022-12-31 0000849636 us-gaap:ConvertibleNotesPayableMember 2023-06-30 0000849636 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0000849636 RSPI:SYCorporationMember 2023-06-30 0000849636 RSPI:SYCorporationMember 2022-12-31 0000849636 2023-04-01 2023-06-30 0000849636 2022-04-01 2022-06-30 0000849636 2022-01-01 2022-06-30 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0000849636 us-gaap:CommonStockMember 2022-12-31 0000849636 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000849636 us-gaap:RetainedEarningsMember 2022-12-31 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000849636 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000849636 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000849636 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000849636 2023-01-01 2023-03-31 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0000849636 us-gaap:CommonStockMember 2023-03-31 0000849636 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000849636 us-gaap:RetainedEarningsMember 2023-03-31 0000849636 2023-03-31 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000849636 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000849636 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000849636 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0000849636 us-gaap:CommonStockMember 2023-06-30 0000849636 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000849636 us-gaap:RetainedEarningsMember 2023-06-30 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000849636 us-gaap:CommonStockMember 2021-12-31 0000849636 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000849636 us-gaap:RetainedEarningsMember 2021-12-31 0000849636 2021-12-31 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000849636 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000849636 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000849636 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000849636 2022-01-01 2022-03-31 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000849636 us-gaap:CommonStockMember 2022-03-31 0000849636 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000849636 us-gaap:RetainedEarningsMember 2022-03-31 0000849636 2022-03-31 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000849636 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000849636 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000849636 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000849636 RSPI:SeriesBConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000849636 RSPI:SeriesI8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000849636 RSPI:SeriesJ8PercentageRedeemablePreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000849636 us-gaap:CommonStockMember 2022-06-30 0000849636 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000849636 us-gaap:RetainedEarningsMember 2022-06-30 0000849636 2022-06-30 0000849636 RSPI:CantheonCapitalMember 2023-05-18 0000849636 RSPI:CantheonCapitalMember 2023-05-18 2023-05-18 0000849636 2023-05-11 0000849636 2022-01-01 2022-12-31 0000849636 2023-05-22 0000849636 RSPI:OfficerAndAffiliateMember 2023-05-22 0000849636 RSPI:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-06-30 0000849636 RSPI:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-06-30 0000849636 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-06-30 0000849636 us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-06-30 0000849636 RSPI:CommonStockWarrantsMember 2023-01-01 2023-06-30 0000849636 RSPI:CommonStockWarrantsMember 2022-01-01 2022-06-30 0000849636 RSPI:CommonStockOptionsMember 2023-01-01 2023-06-30 0000849636 RSPI:CommonStockOptionsMember 2022-01-01 2022-06-30 0000849636 RSPI:SYCorporationMember 2023-01-01 2023-06-30 0000849636 RSPI:NovemberFiveTwoThousandAndFourteenMember 2023-01-01 2023-06-30 0000849636 RSPI:NovemberFiveTwoThousandAndFourteenMember 2023-06-30 0000849636 RSPI:NovemberFiveTwoThousandAndFourteenOneMember 2023-01-01 2023-06-30 0000849636 RSPI:NovemberFiveTwoThousandAndFourteenOneMember 2023-06-30 0000849636 RSPI:NovemberFiveTwoThousandAndFourteenTwoMember 2023-01-01 2023-06-30 0000849636 RSPI:NovemberFiveTwoThousandAndFourteenTwoMember 2023-06-30 0000849636 RSPI:ConvertibleNotesPayableOneMember 2023-06-30 0000849636 RSPI:ConvertibleNotesPayableOneMember 2023-01-01 2023-06-30 0000849636 RSPI:DecemberThirtyOneAndTwoThousandAndEighteenMember 2023-01-01 2023-06-30 0000849636 RSPI:DecemberThirtyOneAndTwoThousandAndEighteenMember 2023-06-30 0000849636 RSPI:JanuaryTwoTwoThousandAndNineteenMember 2023-01-01 2023-06-30 0000849636 RSPI:JanuaryTwoTwoThousandAndNineteenMember 2023-06-30 0000849636 RSPI:ConvertibleNotesPayableTwoMember 2023-06-30 0000849636 RSPI:ConvertibleNotesPayableTwoMember 2023-01-01 2023-06-30 0000849636 RSPI:MaySeventeenTwoThousandAndTwentyMember 2023-01-01 2023-06-30 0000849636 RSPI:MaySeventeenTwoThousandAndTwentyMember 2023-06-30 0000849636 RSPI:JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember 2023-01-01 2023-06-30 0000849636 RSPI:JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember 2023-06-30 0000849636 RSPI:FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember 2023-01-01 2023-06-30 0000849636 RSPI:FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember 2023-06-30 0000849636 RSPI:AprilOneTwoThousandAndTwentyOneConvertibleNoteMember 2023-01-01 2023-06-30 0000849636 RSPI:AprilOneTwoThousandAndTwentyOneConvertibleNoteMember 2023-06-30 0000849636 RSPI:MayThreeTwoThousandAndTwentyOneConvertibleNoteMember 2023-01-01 2023-06-30 0000849636 RSPI:MayThreeTwoThousandAndTwentyOneConvertibleNoteMember 2023-06-30 0000849636 RSPI:MayTenTwoThousandAndTwentyOneConvertibleNoteMember 2023-01-01 2023-06-30 0000849636 RSPI:MayTenTwoThousandAndTwentyOneConvertibleNoteMember 2023-06-30 0000849636 RSPI:JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember 2023-01-01 2023-06-30 0000849636 RSPI:JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember 2023-06-30 0000849636 RSPI:AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember 2023-01-01 2023-06-30 0000849636 RSPI:AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember 2023-06-30 0000849636 RSPI:OctoberSevenTwoThousandTwentyOneMember 2023-01-01 2023-06-30 0000849636 RSPI:OctoberSevenTwoThousandTwentyOneMember 2023-06-30 0000849636 RSPI:DecemberTwentyThreeTwoThousandOneMember 2023-01-01 2023-06-30 0000849636 RSPI:DecemberTwentyThreeTwoThousandOneMember 2023-06-30 0000849636 RSPI:AprilFourteenTwoThousandTwentyTwoMember 2023-01-01 2023-06-30 0000849636 RSPI:AprilFourteenTwoThousandTwentyTwoMember 2023-06-30 0000849636 RSPI:AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember 2023-01-01 2023-06-30 0000849636 RSPI:AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember 2023-06-30 0000849636 RSPI:AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember 2023-01-01 2023-06-30 0000849636 RSPI:AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember 2023-06-30 0000849636 RSPI:AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember 2023-01-01 2023-06-30 0000849636 RSPI:AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember 2023-06-30 0000849636 RSPI:ConvertibleNotesPayableThreeMember 2023-06-30 0000849636 RSPI:ConvertibleNotesPayableThreeMember 2023-01-01 2023-06-30 0000849636 us-gaap:ConvertibleNotesPayableMember 2023-06-30 0000849636 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-06-30 0000849636 RSPI:OriginalConvertibleNotesMember 2023-06-30 0000849636 RSPI:OriginalConvertibleNotesMember 2023-01-01 2023-06-30 0000849636 RSPI:SingleInvestorMember us-gaap:ConvertibleNotesPayableMember 2023-06-30 0000849636 RSPI:FourteenConvertibleNotesMember 2023-06-30 0000849636 RSPI:SYCorporationMember 2012-06-25 0000849636 RSPI:SYCorporationMember 2023-04-01 2023-06-30 0000849636 RSPI:SYCorporationMember 2022-04-01 2022-06-30 0000849636 RSPI:SYCorporationMember 2022-01-01 2022-06-30 0000849636 RSPI:DrArnoldSLippaMember 2023-04-01 2023-06-30 0000849636 RSPI:DrArnoldSLippaMember 2022-04-01 2022-06-30 0000849636 RSPI:DrArnoldSLippaMember 2023-01-01 2023-06-30 0000849636 RSPI:DrArnoldSLippaMember 2022-01-01 2022-06-30 0000849636 RSPI:DrArnoldSLippaMember 2023-06-30 0000849636 us-gaap:RelatedPartyMember 2023-06-30 0000849636 RSPI:ArnoldLippaMember 2023-05-22 0000849636 RSPI:ArnoldLippaMember 2023-05-12 0000849636 RSPI:ArnoldLippaMember us-gaap:MeasurementInputOptionVolatilityMember 2023-05-22 2023-05-22 0000849636 RSPI:ArnoldLippaMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-05-22 2023-05-22 0000849636 2023-05-22 2023-06-30 0000849636 srt:DirectorMember 2023-05-22 0000849636 us-gaap:MeasurementInputOptionVolatilityMember 2023-05-22 2023-05-22 0000849636 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-05-22 2023-05-22 0000849636 srt:DirectorMember 2023-05-22 2023-06-30 0000849636 RSPI:DrJamesSManusosMember 2023-04-01 2023-06-30 0000849636 RSPI:DrJamesSManusosMember 2022-04-01 2022-06-30 0000849636 RSPI:DrJamesSManusosMember 2023-01-01 2023-06-30 0000849636 RSPI:DrJamesSManusosMember 2022-01-01 2022-06-30 0000849636 RSPI:DrManusoMember 2023-06-30 0000849636 RSPI:DrManusoMember 2022-12-31 0000849636 RSPI:OtherShortTermNotesPayableMember 2023-06-30 0000849636 RSPI:OtherShortTermNotesPayableMember 2023-05-01 2023-05-31 0000849636 RSPI:NineMonthlyInstallmentsMember 2023-01-01 2023-06-30 0000849636 RSPI:OtherShortTermNotesPayableMember 2023-03-31 0000849636 RSPI:OtherShortTermNotesPayableMember 2022-12-31 0000849636 RSPI:SecondAmendmentMember 2022-12-15 0000849636 RSPI:SecondAmendmentMember 2022-12-31 0000849636 srt:MinimumMember RSPI:SecondAmendmentMember 2022-12-15 0000849636 RSPI:FormerLegalCounselMember RSPI:SettlementAgreementMember 2022-08-01 0000849636 RSPI:FormerLegalCounselMember RSPI:SettlementAgreementMember 2022-12-30 0000849636 RSPI:FormerLegalCounselMember RSPI:SettlementAgreementMember 2023-02-15 0000849636 RSPI:FormerLegalCounselMember RSPI:SettlementAgreementMember 2023-06-30 0000849636 RSPI:EmploymentAgreementTerminationAndSeparationAgreementMember 2022-01-31 0000849636 us-gaap:ConvertibleNotesPayableMember RSPI:UniversityofCaliforniaInnovationandEntrepreneurshipMember RSPI:PaymentandSettlementAgreementMember 2021-04-29 0000849636 us-gaap:ConvertibleNotesPayableMember RSPI:UniversityofCaliforniaInnovationandEntrepreneurshipMember RSPI:PaymentandSettlementAgreementMember 2022-03-31 0000849636 us-gaap:ConvertibleNotesPayableMember RSPI:UniversityofCaliforniaInnovationandEntrepreneurshipMember RSPI:PaymentandSettlementAgreementMember 2023-06-30 0000849636 us-gaap:ConvertibleNotesPayableMember RSPI:UniversityofCaliforniaInnovationandEntrepreneurshipMember RSPI:PaymentandSettlementAgreementMember 2023-01-01 2023-03-31 0000849636 RSPI:SharpClinicalServicesIncMember 2020-02-20 2020-02-21 0000849636 RSPI:SharpClinicalServicesIncMember 2020-05-26 2020-05-29 0000849636 RSPI:SharpClinicalServicesIncMember 2021-07-28 2021-08-01 0000849636 us-gaap:RelatedPartyMember RSPI:SharpClinicalServicesIncMember 2023-03-31 0000849636 RSPI:SharpSettlementAgreementMember 2023-01-01 2023-03-31 0000849636 RSPI:SharpClinicalServicesIncMember 2022-03-26 2022-03-28 0000849636 us-gaap:RelatedPartyMember RSPI:SalamandraLLCMember 2017-01-18 0000849636 RSPI:SalamandraLLCMember 2017-01-17 2017-01-18 0000849636 RSPI:SalamandraLLCMember 2018-02-26 0000849636 RSPI:SalamandraLLCMember 2023-06-30 0000849636 RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2021-09-14 0000849636 RSPI:NovemberFifteeenTwoThousandAndTwentyOneMember RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2021-09-13 2021-09-14 0000849636 RSPI:NovemberFifteeenTwoThousandAndTwentyTwoMember RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2021-09-13 2021-09-14 0000849636 RSPI:NovemberFifteeenTwoThousandAndTwentyThreeMember RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2021-09-13 2021-09-14 0000849636 RSPI:NovemberFifteeenTwoThousandAndTwentyFourMember RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2021-09-13 2021-09-14 0000849636 RSPI:UpfrontFeesMember RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2023-03-13 2023-03-14 0000849636 RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2021-12-31 0000849636 RSPI:DNAHealthlinkSettlementAgreementMember RSPI:DNAHealthlinkIncMember 2023-06-30 0000849636 RSPI:InvestmentBankingServicesMember 2016-07-21 0000849636 us-gaap:SeriesBPreferredStockMember RSPI:MayOneThousandNineHundredNinetyOneMember 2022-06-30 0000849636 us-gaap:SeriesBPreferredStockMember RSPI:MayOneThousandNineHundredNinetyOneMember 2022-12-31 0000849636 us-gaap:SeriesBPreferredStockMember 2022-12-31 0000849636 us-gaap:SeriesHPreferredStockMember 2023-01-01 2023-06-30 0000849636 RSPI:SeriesIPreferredStockMember 2023-04-02 2023-04-03 0000849636 RSPI:SeriesIPreferredStockMember 2023-04-03 0000849636 RSPI:SeriesIPreferredStockMember 2023-04-03 2023-04-03 0000849636 RSPI:SeriesIPreferredStockMember 2023-04-05 2023-06-15 0000849636 RSPI:SeriesIPreferredStockMember 2023-04-05 2023-06-30 0000849636 RSPI:SeriesIPreferredStockMember 2023-06-30 0000849636 RSPI:SeriesJPreferredStockMember 2023-04-12 2023-04-12 0000849636 RSPI:SeriesJPreferredStockMember 2023-04-12 0000849636 RSPI:SeriesJPreferredStockMember 2023-06-30 0000849636 2023-04-12 2023-06-30 0000849636 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000849636 RSPI:InTheMoneyCommonStockWarrantsMember us-gaap:CommonStockMember 2023-06-30 0000849636 RSPI:ConvertibleNotesThreeMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-07-01 2023-08-21 0000849636 RSPI:ConvertibleNotesThreeMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-08-21 0000849636 RSPI:InTheMoneyCommonStockWarrantsMember 2023-06-30 0000849636 RSPI:TwoThousandFourteenEquityPlanMember 2023-06-30 0000849636 RSPI:TwoThousandFourteenEquityPlanMember 2023-06-07 2023-06-07 0000849636 RSPI:TwoThousandFifteenStockAndStockOptionyPlanMember 2023-06-30 0000849636 RSPI:InTheMoneyCommonStockOptionsMember 2023-06-30 0000849636 RSPI:TwoThousandFourteenEquityPlanMember 2023-01-01 2023-06-30 0000849636 RSPI:TwoThousandFifteenEquityPlanMember 2023-01-01 2023-06-30 0000849636 RSPI:ConvertibleNotesMember 2023-01-01 2023-06-30 0000849636 2021-01-01 2021-12-31 0000849636 RSPI:ExercisePriceRangeOneMember us-gaap:WarrantMember 2023-06-30 0000849636 srt:MinimumMember RSPI:ExercisePriceRangeOneMember us-gaap:WarrantMember 2023-06-30 0000849636 srt:MaximumMember RSPI:ExercisePriceRangeOneMember us-gaap:WarrantMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeTwoMember us-gaap:WarrantMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeThreeMember us-gaap:WarrantMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeFourMember us-gaap:WarrantMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeFiveMember us-gaap:WarrantMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeSixMember us-gaap:WarrantMember 2023-06-30 0000849636 us-gaap:WarrantMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeOneMember us-gaap:WarrantMember 2022-06-30 0000849636 srt:MinimumMember RSPI:ExercisePriceRangeOneMember us-gaap:WarrantMember 2022-06-30 0000849636 srt:MaximumMember RSPI:ExercisePriceRangeOneMember us-gaap:WarrantMember 2022-06-30 0000849636 RSPI:ExercisePriceRangeTwoMember us-gaap:WarrantMember 2022-06-30 0000849636 RSPI:ExercisePriceRangeThreeMember us-gaap:WarrantMember 2022-06-30 0000849636 RSPI:ExercisePriceRangeFourMember us-gaap:WarrantMember 2022-06-30 0000849636 srt:MinimumMember RSPI:ExercisePriceRangeFiveMember us-gaap:WarrantMember 2022-06-30 0000849636 srt:MaximumMember RSPI:ExercisePriceRangeFiveMember us-gaap:WarrantMember 2022-06-30 0000849636 RSPI:ExercisePriceRangeFiveMember us-gaap:WarrantMember 2022-06-30 0000849636 us-gaap:WarrantMember 2022-06-30 0000849636 RSPI:ExercisePriceRangeOneMember 2023-01-01 2023-06-30 0000849636 RSPI:ExercisePriceRangeOneMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeTwoMember 2023-01-01 2023-06-30 0000849636 RSPI:ExercisePriceRangeTwoMember 2023-06-30 0000849636 RSPI:ExercisePriceRangeThreeMember 2023-01-01 2023-06-30 0000849636 RSPI:ExercisePriceRangeThreeMember 2023-06-30 0000849636 srt:MinimumMember RSPI:ExercisePriceRangeFourMember 2023-01-01 2023-06-30 0000849636 srt:MaximumMember RSPI:ExercisePriceRangeFourMember 2023-01-01 2023-06-30 0000849636 RSPI:ExercisePriceRangeFourMember 2023-06-30 0000849636 RSPI:AuroraCapitalLLCMember 2023-01-01 2023-06-30 0000849636 RSPI:PhantomMember 2023-06-30 0000849636 RSPI:JeffMargolisMember 2023-01-01 2023-06-30 0000849636 RSPI:ArnoldLippaMember 2023-01-01 2023-06-30 0000849636 RSPI:JosephR.SiegelbaumMember 2023-01-01 2023-06-30 0000849636 RSPI:FiveVendorsMember 2023-01-01 2023-06-30 0000849636 RSPI:MargolisAndArnoldLippaMember 2023-06-07 2023-06-07 0000849636 RSPI:RichardPurcellMember RSPI:DNAHealthlinkIncMember RSPI:ConsultingAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:DavidDickasonMember 2023-01-01 2023-06-30 0000849636 RSPI:DavidDickasonMember 2022-01-01 2022-06-30 0000849636 2021-07-12 0000849636 RSPI:ThreeInstallmentsMember 2021-07-12 0000849636 RSPI:MilwaukeeOutreachServicesAgreementMember 2022-06-30 0000849636 us-gaap:SubsequentEventMember 2023-08-01 0000849636 us-gaap:SubsequentEventMember 2023-08-01 2023-08-01 0000849636 RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2014-06-25 2014-06-27 0000849636 RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2014-06-27 0000849636 RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2015-06-30 2015-06-30 0000849636 RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2021-01-01 2021-12-31 0000849636 RSPI:TwoThousandAndFourteenLicenseAgreementMember 2021-12-29 2021-12-31 0000849636 RSPI:FirstTimedPaymentsMember 2023-01-01 2023-06-30 0000849636 RSPI:SecondTimedPaymentsMember 2023-01-01 2023-06-30 0000849636 RSPI:TwoThousandAndFourteenLicenseAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:AfterFirstYearMember RSPI:TwoThousandAndFourteenLicenseAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:DueWithinFiveDaysAfterDosingOfFirstPatientPhaseTwoHumanClinicalTrialMember RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:DueWithinFiveDaysAfterDosingOfFirstPatientPhaseThreeHumanClinicalTrialMember RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:DueWithinFiveDaysAfterDosingOfFirstPatientPhaseThreeHumanClinicalTrialMember RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementThreeMember 2023-01-01 2023-06-30 0000849636 RSPI:DueWithinFiveDaysAfterFirstNewDrugApplicationFilingMember RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:DueWithinTwelveMonthsOfFirstCommercialSaleMember RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2023-01-01 2023-06-30 0000849636 RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2022-01-01 2022-06-30 0000849636 RSPI:UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember 2022-01-01 2022-12-31 0000849636 srt:ScenarioForecastMember RSPI:DrArnoldSLippaMember 2023-04-01 2023-09-30 0000849636 srt:ScenarioForecastMember RSPI:MrMargolisMember 2023-04-01 2023-09-30 0000849636 srt:ScenarioForecastMember 2023-04-01 2023-09-30 0000849636 us-gaap:LicensingAgreementsMember 2023-06-30 0000849636 RSPI:EmploymentAgreementMember 2023-06-30 0000849636 us-gaap:SubsequentEventMember RSPI:ShareTransferAgreementMember 2023-08-03 0000849636 us-gaap:SubsequentEventMember 2023-08-18 0000849636 us-gaap:SubsequentEventMember 2023-07-11 2023-08-18 iso4217:USD shares iso4217:USD shares iso4217:KRW pure 0000849636 false Q2 --12-31

P1Y

10-Q true 2023-06-30 2023 false 1-16467 RESPIRERX PHARMACEUTICALS INC. DE 33-0303583 126 Valley Road Suite C Glen Rock NJ 07452 (201) 444-4947 Not applicable Yes Yes Non-accelerated Filer true false false 275728647

7321

6661

50105

77189

22693

141276

22781

141276

22781

5889542

5724390

3446608

3296008

381026

252881

1289854 1258315

531251

507330

819738

833463

466465

375334

236938

225744

236938

225744

60483

15847

12209628

11729101

74000

174000

74000

174000

12283628

11903101

0.001

0.6667

25001

37500

0.000030

21703

0.001

100.00

3500

709

70891

0.001

100.00

15000

5799

579870

0.001

2000000000

220728647

125544276

220729

125544

164133404

164030289

-177168949

-176057856

-12142352

-11880320

141276

22781

367644

211376

659562

707170

98215

141099

196640

262257

465859

352475

856202

969427

-465859

-352475

-856202

-969427

225049

179521

292321

439169

9878

51708

37430

68145

-681030

-480288

-1111093

-1340451

-10761 -351738 -10761 -351738

-691791

-832026

-1121854

-1692189

-0.004

-0.008

-0.007

-0.017

168213521

106081803

158402599

102010657

37500

21703

125544276

125544

164030289

-176057856

-11880320

18782396 18783 -18783 0

-430063

37500

21703

144326672

144327

164011506

-176487919

-12310383

700 70000 70000 9 891 -891 0 5700 570000 570000 99 9870 -9870 0

56039999

56040

28021

84061

20361976 20362 -20362 0

125000

-681030

37500

21703

709

70891

5799

579870

220728647

220729

164133404

-177168949

-12142352

37500

21703

97894276

97894

163827781

-173955136

-10007758

-860163

37500

21703

97894276

97894

163827781

-174815299

-10867921

37500

21703

97894276

97894

163827781

-174815299

-10867921

25000

19175000

19175

172575

191750

-480288

37500

21703

117069276

117069

164025356

-175295587

-11131459

37500

21703

117069276

117069

164025356

-175295587

-11131459

-1111093

-1340451

11076

336728

37646

68145

6661

-177883

104601

-47619

205970

304382

360600

360100

-340312

184276

96762

-157767

-85122

70000

25000

95000 1500 -37752

94997

165000

83745

7233

-1377

1398

7321

4728

5657

11075 96470 95850

100000

60000

25000

570000 84060 190250 39145

<p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zC8JArmprdei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. Organization and Basis of Presentation Organization RespireRx Pharmaceuticals Inc. (“RespireRx”) was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. In August 2012, RespireRx acquired Pier Pharmaceuticals, Inc. (“Pier”), which is now a wholly-owned subsidiary. Pier was a clinical stage biopharmaceutical company developing a pharmacologic treatment for obstructive sleep apnea (“OSA”) and had been engaged in research and clinical development activities which activities are now in RespireRx’s wholly-owned subsidiary ResolutionRx Ltd (“ResolutionRx”). On January 11, 2023, RespireRx formed as a wholly-owned subsidiary, ResolutionRx, an unlisted public company in Australia, into which RespireRx, as of August 3, 2023, has contributed its cannabinoid platform described below. Basis of Presentation The condensed consolidated financial statements are of RespireRx and its wholly-owned subsidiaries, Pier and ResolutionRx (collectively referred to herein as the “Company,” “we” or “our,” unless the context indicates otherwise). The condensed consolidated financial statements and related notes are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and other information included in the Company’s Annual Report in our Form 10-K for the fiscal year ended December 31, 2022 as filed with the SEC on April 17, 2023 (“2022 Form 10-K”).

2. Business The mission of the Company is to develop innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling. We are developing treatment options that address conditions affecting millions of people, but for which there are limited or poor treatment options, including OSA, attention deficit hyperactivity disorder (“ADHD”), epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, recovery from spinal cord injury (“SCI”) and certain orphan disorders. We are also considering developing treatment options for other conditions based on results of preclinical and clinical studies to date. To achieve these goals, the Company has determined that some or all of these opportunities should be contributed to what could be, wholly-owned subsidiaries, joint ventures, licenses or sub-licenses, or even sold and has initiated efforts to do so. In order to facilitate our business activities and product development and to set up our programs for development by subsidiaries, partnering or sale, we have implemented an internal restructuring plan based upon our two research platforms: pharmaceutical cannabinoids and neuromodulators. As of January 11, 2023, RespireRx had formed ResolutionRx, initially a wholly-owned subsidiary focused on pharmaceutical cannabinoids and previously, EndeavourRx, as a business unit focused on our neuromodulators. The Company will use, at least initially, its management personnel to provide management, research and development, operational and oversight services to these two lines of business. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">ResolutionRx, our pharmaceutical cannabinoids subsidiary is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of OSA. Dronabinol is already approved by the FDA for other indications. </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">EndeavourRx, our neuromodulators platform is made up of two programs: (a) our AMPAkines program, which is developing proprietary compounds that act as positive allosteric modulators (“PAMs”) of AMPA-type glutamate receptors to promote neuronal function and (b) our GABAkines program, which is developing proprietary compounds that act as PAMs of GABAA receptors, and which was established pursuant to our entry into a patent license agreement (the “UWMRF Patent License Agreement”) with the University of Wisconsin-Milwaukee Research Foundation, Inc., an affiliate of the University of Wisconsin-Milwaukee (“UWMRF”).</td></tr> </table> Like ResolutionRx, which as of January 11, 2023, was organized as a wholly-owned subsidiary, of RespireRx, management also intends to organize our EndeavourRx business unit, in part or in whole, into one or more subsidiaries that would conduct research and development of our neuromodulator platform, including either or both of the AMPAkine and GABAkine programs and their related tangible and intangible assets and certain of their liabilities. The Company’s business development efforts (licensing, sub-licensing, joint venture and other commercial structures), if successful, would represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. These efforts have focused on, but have not been limited to, seeking transactions with brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful clinical development, formulation or manufacturing capabilities, significant subject matter expertise and financial resources. No assurance can be given that any transaction will come to fruition and that, if it does, the terms will be favorable to the Company. Financing our Platforms Our major challenge has been to raise substantial equity or equity-linked financing to support research and development plans for our cannabinoid and neuromodulator platforms, while minimizing the dilutive effect to pre-existing stockholders. At present, we believe that we are hindered primarily by our public corporate structure, our OTC Pink Market listing and our low market capitalization as a result of our low stock price as well as the weakness of our balance sheet. For this reason, the Company has affected an internal restructuring plan described above that we believe will further the aims of RespireRx, ResolutionRx and EndeavourRx, and may make it possible, through separate finance channels, to unlock the unrealized asset values of each and set up its programs for partnering or sale. The Company is also engaged in business development efforts (licensing/sublicensing, joint venture and other commercial structures) with a view to securing strategic partnerships that represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. We believe that some or all of our assets should be licensed, sublicensed, joint ventured or even sold and have initiated efforts to do so. No assurance can be given that any transaction will come to fruition and that if it does, that the terms will be favorable to the Company. On May 18, 2023, ResolutionRx entered into a Letter of Intent with Cantheon Capital (“Cantheon” and “Cantheon LOI”) that describes an intended investment of US$3,125,000 by Cantheon in Australian Series A Preference Shares to be issued by ResolutionRx to support clinical trial research and development over the R&D period equal to <span id="xdx_90E_ecustom--ResearchAndDevelopmentClinicalTrailCostsPercentage_dp_c20230518__20230518__srt--ConsolidatedEntitiesAxis__custom--CantheonCapitalMember_zppae19LD1Qh" title="Clinical trail costs percentage">25% of the clinical trial costs of the cannabinoid program that are the subject of the Australian CRO Agreement with iNGENu. On May 11, 2023, RespireRx entered into a Letter Agreement (“Letter Agreement”) with Viridian Capital Advisors (“VCA”) pursuant to which, VCA would perform the following services (“Valuation Services”): (i) review the Company’s intellectual property assets and licensing agreements as they relate to Company’s cannabinoid program, net of any associated liabilities, (ii) review the Company’s financial models and forecasts as they relate to the Company’s cannabinoid program and (iii) prepare the data, analytics and Company valuation analysis (“Valuation Analysis”) specifically with respect to the Company’s cannabinoid program. The Letter Agreement became effective on May 22, 2023. The Company entered this Letter Agreement as part of the process that began with the establishment of ResolutionRx, into which the net assets of the Company’s cannabinoid program have been contributed via license and sublicense in exchange for 25,000,000 Ordinary Shares of ResolutionRx, all as of August 3, 2023. RespireRx received the final Valuation Analysis on August 7, 2023. See Note 9. Subsequent Events. On August 3, 2023, Respirerx entered into a License Agreement with ResolutionRx See Note 9. Subsequent Events - Entry into License Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx entered into a Sublicense Agreement with ResolutionRx - See Note 9. Subsequent Events - Entry into Sublicense Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx entered into a Stock Transfer Agreement with ResolutionRx - See Note 9. Subsequent Events – Entry into Stock Transfer Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx entered into a Master Intercompany Services Agreement with ResolutionRx - See Note 9. Subsequent Events – Entry into Master Intercompany Services Agreement with ResolutionRx Ltd Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses and net losses attributable to common stockholders of $681,030 and $691,791 for the three-months ended June 30, 2023, respectively, and net losses and net losses attributable to common stockholders of $1,111,093 and $1,121,854 for the and six-months ended June 30, 2023, respectively. The 2023 net losses attributable to common stockholders was after accounting for dividends on the Series I Preferred Stock and Series J Preferred Stock. The Company incurred a net a loss of $480,288 and $1,340,451 for the three-months and six-months ended June 30, 2022, respectively and a net loss attributable to common stockholders of $832,026 and $1,692,189 for the three-months and six-months ended June 30, 2022 after accounting for deemed dividends associated with most-favored nation provisions of convertible notes, and a total net loss of $3,972,993 for the fiscal year ended December 31, 2022, as well as negative operating cash flows of $157,767 for the six-months ended June 30, 2023 and $143,905 for the fiscal year ended December 31, 2022. The Company also had a stockholders’ deficiency of $12,142,352 at June 30, 2023 and expects to continue to incur net losses and negative operating cash flows for at least the next few years. Additionally, as of June 30, 2023, the Company has, with respect to fourteen similar convertible notes outstanding after eight partial conversions of principal or interest during the three-months and six-months ended June 30, 2023, $1,289,854 maturity amount inclusive of accrued interest which have matured, but for which no notices of default have been received, which must be paid or converted. See Note 4. Notes Payable. The Company will seek to have maturity dates extended in order to avoid a default on such convertible notes, which the Company has achieved in the past, but with respect to which, the Company can provide no assurance. The Company has also not met its payment obligations to the UWM Research Foundation (“UWMRF”) of the University of Wisconsin-Milwaukee but has not received a notice of default and is in regular communication with the UWMRF regarding the establishment of a payment schedule. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, and the Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2022, expressed substantial doubt about the Company’s ability to continue as a going concern. The Company is currently, and has for some time, been in significant financial distress. It has extremely limited cash resources and current assets and has no ongoing source of sustainable revenue. Management is continuing to address various aspects of the Company’s operations and obligations, including, without limitation, debt obligations, financing requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance, and has taken steps to continue to raise new debt and equity capital to fund the Company’s business activities from both related and unrelated parties. The Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its business activities on a going forward basis, including the pursuit of the Company’s planned research and development activities. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including development and other agreements with collaborative partners and, when necessary, seeking to exchange or restructure the Company’s outstanding securities and liabilities. The Company is evaluating certain changes to its operations and structure to facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s development programs and, in that regard, has formed an Australian subsidiary, ResolutionRx. In addition to the formation of ResolutionRx, such changes could include additional significant reorganizations, which may include the formation of one or more additional subsidiaries into which one or more programs may be contributed. As a result of the Company’s current financial situation, the Company has limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate.

3125000

0.25 25000000

-681030

-691791

-1111093

-1121854

-480288

-1340451

-832026

-1692189

-3972993

-157767

-143905

-12142352

1289854

3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include the financial statements of RespireRx and its wholly-owned subsidiaries, Pier and ResolutionRx. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. Value of Financial Instruments The authoritative guidance with respect to value of financial instruments established a value hierarchy that prioritizes the inputs to valuation techniques used to measure value into three levels and requires that assets and liabilities carried at value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded, non-exchange based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the value hierarchy within which each value measurement falls in its entirety, based on the lowest level input that is significant to the value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, and accounts payable and accrued expenses) are considered by the Company to be representative of the respective values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date for companies like the Company. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective values of such instruments due to the short-term nature of those instruments and their terms. Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned or is unlikely to be completed. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed equity financings are netted against the proceeds. Capitalized Financing Costs The Company presents debt issuance costs related to debt obligations in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt obligation, consistent with the presentation for debt discounts. Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants or commitment shares of Common Stock, the convertible notes and equity or equity-linked securities are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued in connection with and at the time of such financing. Debt and Other Liability Exchanges In cases where debt or other liabilities are exchanged for equity, the Company compares the carrying value of debt, inclusive of accrued interest, if applicable, being exchanged, to the fair value of the equity issued and records any loss or gain as a result of such exchange. See Note 4. Notes Payable. Extinguishment of Debt and Settlement of Liabilities The Company accounts for the extinguishment of debt and settlement of liabilities by comparing the carrying value of the debt or liability to the value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. Prepaid Insurance Prepaid insurance represents the premium that was due in March 2023 for directors and officers insurance. The amounts of prepaid insurance amortizable in the ensuing twelve-month period are recorded as prepaid insurance in the Company’s condensed consolidated balance sheet at each reporting date and amortized to the Company’s condensed consolidated statement of operations for each reporting period. Stock-Based Awards The Company periodically issues common stock and stock options and phantom stock (collectively, “Stock-Based Awards”) to officers, directors, Scientific Advisory Board members, consultants and other vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated or condensed consolidated financial statements, as appropriate, over the vesting period of the awards. Stock grants, which are sometimes subject to time-based vesting, are measured at the grant date fair value of the common stock and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s outside consultants and other vendors are valued on the grant date. As the stock options vest, the Company recognizes this expense over the period in which the services are provided. The value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the estimated life of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock options and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. Phantom stock awards, which are sometimes subject to time-based vesting, are measured at the award date fair value, if measurable. As the phantom stock awards vest, the Company recognizes the expense, if measurable, upon vesting. To the extent that the value of phantom stock awards is not measurable on the award date, measurement only being possible on the satisfaction of certain contingent events that may not be predictable and measurable at the time of the award, the Company recognizes the expense as a change in an estimate as of the date on which the contingent event becomes predictable and measurable. The Company recognizes the value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated or condensed consolidated statements of operations, as appropriate. The Company issues new shares of Common Stock to satisfy stock option and warrant exercises. There were no stock or stock option grants during the three-months or six-months ended June 30, 2023. There were no stock options exercised during the three-months or six months ended June 30, 2023 and 2022. There were no warrants issued as compensation or for services during the three-months and six-months ended June 30, 2023 and 2022. There were warrants exercisable into 83,333,333 shares of the RespireRx’s Common Stock issued on May 22, 2023 with respect to the issuance of $250,000 of demand promissory notes to an affiliate of an officer and another affiliate. Warrants, if issued for services, are typically issued to placement agents or brokers for fund raising services, or to lenders, and are not issued from any of the Company’s stock and option plans, from which options issued to non-employees for services are typically issued. Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of June 30, 2023, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of June 30, 2023, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The accounts for ResolutionRx are maintained in Australian dollars and are converted to U.S. dollars at the exchange rate on the balance sheet. In both cases, the foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations. Research and Development Research and development costs include compensation paid to management directing RespireRx’s research and development activities, including but not limited to compensation paid to our Chief Scientific Officer who is also our Executive Chairman, our Interim President and our Interim Chief Executive Officer and who has similar roles at ResolutionRx, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates. License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate term, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development expenses in the Company’s condensed consolidated statement of operations. Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses. Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net loss attributable to common stockholders consists of net loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQJeLvj5KKZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At June 30, 2023 and 2022 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20230630_zZ7dZNmTeK1b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630_zG8XDspCRLbf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zWKbNOC1xwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Series B convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zbYsFHqjZKa9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">660,982,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,699,516</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziFCUYv5t1j6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,192,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,310,598</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zI8SCdwulOwa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,168,317</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,221,445</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zELIcMJ3r5fj" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">1,123,343,728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630_zMj0qE17aU7f" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">186,231,560</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Reclassifications Certain comparative figures in 2022 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate. Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This Accounting Standard Update (“ASU”) addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The Company has historically issued complex financial instruments and has considered whether embedded conversion features have existed within those contracts or whether derivatives would appropriately be bifurcated. To date, no such bifurcation has been necessary. Management has evaluated the potential impact and has early adopted this ASU as of January 1, 2022. Management believes the adoption has simplified the accounting for convertible debt instruments and does not believe adoption has had a substantial impact on the financial statements, however, it is possible that this ASU may have a substantial impact on the Company’s financial statements from future convertible debt or preferred stock financings.

Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include the financial statements of RespireRx and its wholly-owned subsidiaries, Pier and ResolutionRx. Intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.

Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.

Value of Financial Instruments The authoritative guidance with respect to value of financial instruments established a value hierarchy that prioritizes the inputs to valuation techniques used to measure value into three levels and requires that assets and liabilities carried at value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently traded, non-exchange based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the value hierarchy within which each value measurement falls in its entirety, based on the lowest level input that is significant to the value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, and accounts payable and accrued expenses) are considered by the Company to be representative of the respective values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date for companies like the Company. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective values of such instruments due to the short-term nature of those instruments and their terms.

Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned or is unlikely to be completed. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed equity financings are netted against the proceeds.

Capitalized Financing Costs The Company presents debt issuance costs related to debt obligations in its condensed consolidated balance sheet as a direct deduction from the carrying amount of that debt obligation, consistent with the presentation for debt discounts.

Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants or commitment shares of Common Stock, the convertible notes and equity or equity-linked securities are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued in connection with and at the time of such financing.

Debt and Other Liability Exchanges In cases where debt or other liabilities are exchanged for equity, the Company compares the carrying value of debt, inclusive of accrued interest, if applicable, being exchanged, to the fair value of the equity issued and records any loss or gain as a result of such exchange. See Note 4. Notes Payable. Extinguishment of Debt and Settlement of Liabilities The Company accounts for the extinguishment of debt and settlement of liabilities by comparing the carrying value of the debt or liability to the value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. Prepaid Insurance Prepaid insurance represents the premium that was due in March 2023 for directors and officers insurance. The amounts of prepaid insurance amortizable in the ensuing twelve-month period are recorded as prepaid insurance in the Company’s condensed consolidated balance sheet at each reporting date and amortized to the Company’s condensed consolidated statement of operations for each reporting period.

Stock-Based Awards The Company periodically issues common stock and stock options and phantom stock (collectively, “Stock-Based Awards”) to officers, directors, Scientific Advisory Board members, consultants and other vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated or condensed consolidated financial statements, as appropriate, over the vesting period of the awards. Stock grants, which are sometimes subject to time-based vesting, are measured at the grant date fair value of the common stock and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s outside consultants and other vendors are valued on the grant date. As the stock options vest, the Company recognizes this expense over the period in which the services are provided. The value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair value of the common stock on the grant date, and the estimated volatility of the common stock over the estimated life of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock options and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. Phantom stock awards, which are sometimes subject to time-based vesting, are measured at the award date fair value, if measurable. As the phantom stock awards vest, the Company recognizes the expense, if measurable, upon vesting. To the extent that the value of phantom stock awards is not measurable on the award date, measurement only being possible on the satisfaction of certain contingent events that may not be predictable and measurable at the time of the award, the Company recognizes the expense as a change in an estimate as of the date on which the contingent event becomes predictable and measurable. The Company recognizes the value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated or condensed consolidated statements of operations, as appropriate. The Company issues new shares of Common Stock to satisfy stock option and warrant exercises. There were no stock or stock option grants during the three-months or six-months ended June 30, 2023. There were no stock options exercised during the three-months or six months ended June 30, 2023 and 2022. There were no warrants issued as compensation or for services during the three-months and six-months ended June 30, 2023 and 2022. There were warrants exercisable into 83,333,333 shares of the RespireRx’s Common Stock issued on May 22, 2023 with respect to the issuance of $250,000 of demand promissory notes to an affiliate of an officer and another affiliate. Warrants, if issued for services, are typically issued to placement agents or brokers for fund raising services, or to lenders, and are not issued from any of the Company’s stock and option plans, from which options issued to non-employees for services are typically issued.

83333333

250000

Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates it will be able to utilize these tax attributes. As of June 30, 2023, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of June 30, 2023, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.

Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The accounts for ResolutionRx are maintained in Australian dollars and are converted to U.S. dollars at the exchange rate on the balance sheet. In both cases, the foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations.

Research and Development Research and development costs include compensation paid to management directing RespireRx’s research and development activities, including but not limited to compensation paid to our Chief Scientific Officer who is also our Executive Chairman, our Interim President and our Interim Chief Executive Officer and who has similar roles at ResolutionRx, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and product candidates.

License Agreements Obligations incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate term, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development expenses in the Company’s condensed consolidated statement of operations.

Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses.

Earnings per Share The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net loss attributable to common stockholders consists of net loss, as adjusted for actual and deemed preferred stock dividends declared, amortized or accumulated. Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQJeLvj5KKZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At June 30, 2023 and 2022 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20230630_zZ7dZNmTeK1b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630_zG8XDspCRLbf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zWKbNOC1xwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Series B convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zbYsFHqjZKa9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">660,982,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,699,516</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziFCUYv5t1j6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,192,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,310,598</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zI8SCdwulOwa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,168,317</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,221,445</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zELIcMJ3r5fj" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">1,123,343,728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630_zMj0qE17aU7f" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">186,231,560</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zQJeLvj5KKZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At June 30, 2023 and 2022 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20230630_zZ7dZNmTeK1b" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630_zG8XDspCRLbf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesBConvertiblePreferredStockMember_zWKbNOC1xwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Series B convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">1</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_zbYsFHqjZKa9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">660,982,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,699,516</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockWarrantsMember_ziFCUYv5t1j6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Common stock warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">453,192,635</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,310,598</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionsMember_zI8SCdwulOwa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Common stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,168,317</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,221,445</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230630_zELIcMJ3r5fj" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">1,123,343,728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20220630_zMj0qE17aU7f" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">186,231,560</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

660982775

83699516

453192635

93310598

9168317

9221445

1123343728

186231560

Reclassifications Certain comparative figures in 2022 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.

Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This Accounting Standard Update (“ASU”) addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The Company has historically issued complex financial instruments and has considered whether embedded conversion features have existed within those contracts or whether derivatives would appropriately be bifurcated. To date, no such bifurcation has been necessary. Management has evaluated the potential impact and has early adopted this ASU as of January 1, 2022. Management believes the adoption has simplified the accounting for convertible debt instruments and does not believe adoption has had a substantial impact on the financial statements, however, it is possible that this ASU may have a substantial impact on the Company’s financial statements from future convertible debt or preferred stock financings.

4. Notes Payable Convertible Notes Payable The table below summarizes all convertible notes outstanding as of June 30, 2023. Those with similar characteristics outstanding as of June 30, 2023 are grouped separately. The following abbreviations are used in the column headings: DIC is Debt Issuance Cost, OID is Original Issue Discount, Wts are warrants, CNC is Capitalized Note Cost and BCF is Beneficial Conversion Feature. Also included are repayments by conversion, exchange or otherwise during or prior to the three-month period ended June 30, 2023: Schedule of Convertible Notes Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Inception Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Maturity date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Original Principal Amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Interest rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Original aggregate DIC, OID, Wts, CNC and BCF</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Cumulative amortization of DIC, OID, Wts, CNC and BCF</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accrued coupon interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Repayment by conversion, increase in principal amount, net where appropriate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Balance sheet carrying amount at June 30, 2023 inclusive</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">November 5, 2014</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_fMQ_____z4br00lYp0Nf" title="Debt Instrument, Maturity Date">September 15, 20161</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_zKhm98A1ajxf" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z7aWosPqaxk9" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z9LssNJtA6rf" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_zYmyFXdM9PR4" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z9z65wCxDmGk" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Interest Payable">32,649</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_zqEeS7faAVuh" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z3BOL6okL0K6" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Balance sheet carrying amount">57,649</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">November 5, 2014</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_fMQ_____zfb21Hx7TUPf" title="Debt Instrument, Maturity Date">September 15, 20161</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_z2hJNYsL5rS9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zE2Ty56kJxoj" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_z9lwQ6lgP2hh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_z5YbbUKeYSTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zw3MYA8xRge9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">32,649</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zE2ByUZkeSrf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zRj5840J0na" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">57,649</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">November 5, 2014</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_fMQ_____zmWVCV33sm2a" title="Debt Instrument, Maturity Date">September 15, 20161</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zCQeVj9XQz17" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zkikgvaDsSF" title="Debt Instrument, Interest Rate, Stated Percentage">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_z2fTMZKhgV37" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zBjGf7kyRac3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zzZ9b9DTMgX9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">42,443</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zJb2uogjUqNl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zZTTeJMJMoc4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">67,443</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Sub-total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zIg7eZFQyPe5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Sub-total">75,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_ztYy0TdGUTfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zXNdiWggz259" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_z5SMIVA6tvXf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">107,741</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zMra7ZkyrR06" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zF4IcwnbdIk9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">182,741</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 31, 2018</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_fMg_____zKtsnQUaY2Z5" title="Debt Instrument, Maturity Date">February 28, 20192</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zGXjomrBUf2h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_z0p9mAhvpkB" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zRzW7HT2LWsd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zXAPmTf8B2Gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zYB3PX7pl4N3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">14,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_z7dLhtpIOj66" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zVERJ3sb0lxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">39,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">January 2, 2019</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_fMg_____zPL7xHdddV2e" title="Debt Instrument, Maturity Date">February 28, 20192</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_z33AimR5RC1j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zrUTxzJ7Rl5e" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zNOpOKs0bCk5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zwP1tnwJvl92" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zM1A3Y2KqpM4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">5,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zB2r6p2yH5Ne" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zitjM7ebDRL8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">15,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Sub-total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zvAbu6b5Wpm6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original principal amount sub-total">35,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zMECuiBMATm1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zqzGUQhCXVZf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_z6YQL11D8vFl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">19,695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zAu8d2sicpe9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zPFIzoCt2V65" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">54,695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">May 17, 2019</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_fMw_____z4w0vkxjSuQ6" title="Debt Instrument, Maturity Date">May 17, 20203</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zONVn3JIvLb5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_z3IPAQNAhSn9" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zdfLDJn3zuKd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zVXWAyKFPmi3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zP2WsTcNshu8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">5,001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zAxot2yg3KH8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(52,253</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zgBBObTkcKoa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">2,748</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">July 28, 2020</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_fMw_____zRpN9NQuHI3e" title="Debt Instrument, Maturity Date">June 30, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zaX9NjTgc9X2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">53,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zSpxX2lr4rT9" title="Debt Instrument, Interest Rate, Stated Percentage">8.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zelUTMpInRf6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(13,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zzQPl0obi0J8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">13,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zasVYXcJ4N7c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">11,196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zdp0MMlD5fwk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(16,247</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_z8gMbYP96E51" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">47,949</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">February 17, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zRUMJpimZyY7" title="Debt Instrument, Maturity Date">June 17, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_znC0CXVzPKhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">112,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zy74vsKzxw37" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_z57iFy8Qg1Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(112,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zMV2iQylinT4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">112,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_znSGKua5YIq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">13,483</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zPg7pMz02lZ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(80,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zKLuzA8PHQz4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">45,483</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">April 1, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____z52sDQpwf41d" title="Debt Instrument, Maturity Date">July 31, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zwySp7FPSzt1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">112,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zxqcFh4Aj4V3" title="Debt Instrument, Interest Rate, Stated Percentage">24.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zH6shNv4dBP8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(112,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zCN0hSz0Anlf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">112,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zJrmF8JcFANh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">67,943</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zkaOUSH6Ub3k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(42,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zfacSaKRTdDd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">138,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">May 3, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zg3iVP9KeZVf" title="Debt Instrument, Maturity Date">July 31, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zgiLZzjGQ7g3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zMXtccQCBMNg" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zifC7kRLZKuj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zbM3GCTm0gN2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_ztHrIkJlewA9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_z7lrhve5lBmi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zEjxX6rxosr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">May 10, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zl2JFI09VRF1" title="Debt Instrument, Maturity Date">August 10, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zwaGJm53IZVc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zBgox7Gnultc" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_ze0GXwjA5mol" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zG3ltf7OL8Sc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_z9ehi1p0stbi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">27,185</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zWtlEHbRttea" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(13,213</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zAfAuaDA9J99" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">163,972</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">June 30, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zCMjLj95dRek" title="Debt Instrument, Maturity Date">June 29, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zjO4MSZXFqi5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zrRvz4frO3c6" title="Debt Instrument, Interest Rate, Stated Percentage">24.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zybzGWRgLbK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zpZkO7UMErJj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zd8ZV9a9LiH7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">35,073</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zEskUa4fXV7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zCtwGyP7yobh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">150,073</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____z5WN2Wr6wfN5" title="Debt Instrument, Maturity Date">August 31, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zwP55t4t30T3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zPwV8sFFZPok" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zqLXcfO1wHVg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(109,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zaWqe8k5xvT7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">109,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zCMHKKuVgX9a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">21,047</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zHVXeZ0ZGQ39" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zZgOiBAP6k6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">136,047</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 7, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_fMw_____z6bqGeb6eBW9" title="Debt Instrument, Maturity Date">October 7, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zMhheuhAqDC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_z0Byud9O4oN5" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zKyW12nWPZEi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(96,705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zG8yZV9fr6j3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">96,705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_za0E1kFwHwWe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">19,881</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zvLcPQya8Xjh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zuAXDf76TARa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">134,881</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 23, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_fMw_____zhlLZMkP8Tja" title="Debt Instrument, Maturity Date">June 21, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zUq5DcsjEf6h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">87,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zYcM9XG35VMb" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zasLj1b6iCO3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(36,301</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_ztAS9M0bxV9k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">36,301</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_z3pQwJVf7I21" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">40,810</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zlL4f0xblNw6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(23,160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zSjU6zNMBRgk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">104,650</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">April 14, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_fMw_____zMWAD3E7Tdnj" title="Debt instrument, maturity date">April 14, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_z93N3U5wHk7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">27,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_z7J33CdEre65" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zl0mEHvc1X13" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(15,936</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zfc1W0i5vRu2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">15,936</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zlSlL8S03Ajd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">3,364</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zRVWgWpIZvs5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_z0lHHTdCHe8l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">31,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 22, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_fMw_____zx2GZSB6DtB7" title="Debt instrument, maturity date">May 31, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zUjoZoYgfDal" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">66,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zDvg06FtT115" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zI1CngbaAR7k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(6,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zGOW3IBPD862" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">6,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zTBSgXHj3Wqd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">5,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zVLj68adP6ke" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zSGACB8IJ2Wf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">72,366</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 22, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_fMw_____zBZ8pdwIKO3j" title="Debt instrument, maturity date">May 31, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zrOkQSwuOmVd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">22,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zrDtC27oEGBj" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zE9sCjYXxLzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(2,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_z0QPsUCKMlw8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">2,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zGyHBB4daqzg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">1,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zawm6eGHRcok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zqQh6CeXP2J1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">24,122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 22, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_fMw_____zAQmk6XmbpM4" title="Debt instrument, maturity date">May 31, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zQo9mhoTjjxj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">16,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zzbhrsR53rYc" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zAqzI5BRr52h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(1,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zUvRP9Mw9xHh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">1,434</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zOTnbCgYAWh8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">1,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zEYqo6AQzCJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_z2Awg16Q0ZK2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">943</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Sub-total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zcoN6Tmpuok4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original principal amount sub-total">1,192,834</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zomvPyGbE227" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original aggregate sub-total">(971,673</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zNZMbGZglzBc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization of DIC, OID, Wts, CS and BCF sub-total">971,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zfERCwsIKhC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued coupon interest sub-total">253,590</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zxL3eClU8QZ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayment by conversion sub-total">(393,773</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_z8nb6spBqmsk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Sub-total">1,052,418</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zgpsLxKA1Glk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">1,302,834</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zqAnTAOHMpjj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original aggregate DIC, OID, Wts, CNC and BCF">(971,673</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zrXPR9GKasOk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization of DIC, OID, Wts, CS and BCF">971,440</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zws3GeZ6acL6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued coupon interest">381,026</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zV8GaYsXjwib" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayment by conversion">(393,773</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z75ZDfRmZhGf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount inclusive of accrued interest">1,289,854</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td id="xdx_F04_zZMjuug3tUJc" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These convertible notes were sold to investors in 2014 and 2015 (“Original Convertible Notes) and have a fixed interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_zF7mEnrx4OQh" title="Fixed interest rate">10% per annum and in the case of the one note for which a notice of default has been received, 12%. The Original Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events and are convertible into an aggregate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_z6dHUIcBxCZ2" title="Conversion of common stock">1,560 shares of Common Stock as of June 30, 2023. As of June 30, 2023, principal and accrued interest on the Original Convertible Note that is subject to a default notice totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_z94fIyjm9qf5" title="Convertible notes">67,443, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_zd5x4azwPjVi" title="Accrued interest">42,443 was accrued interest.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_F0C_zEupfdaCBlbj" style="font: 10pt Times New Roman, Times, Serif">2</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 31, 2018 and January 2, 2019, the Company issued convertible notes to a single investor totaling $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ConvertibleDebt_iI_c20230630__srt--TitleOfIndividualAxis__custom--SingleInvestorMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zUvHdOjAFi7a" title="Convertible notes">35,000 of maturity amount with accrued interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20230630__srt--TitleOfIndividualAxis__custom--SingleInvestorMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z2jR0UJU2K7g" title="Accrued interest">19,695 as of June 30, 2023. The number of shares of common stock (or preferred stock) into which these notes may convert is not determinable.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_F0A_zoQlS0lnG5od" style="font: 10pt Times New Roman, Times, Serif">3</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These fourteen convertible notes were issued between May 17, 2019 and August 22, 2022. They all currently have similar terms including conversion prices that generally are or are likely to be $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230630__us-gaap--DebtInstrumentAxis__custom--FourteenConvertibleNotesMember_zcDTv2LKuTSa" title="Common stock, per share">0.0015 per share of Common Stock. All such notes matured prior to June 30, 2023. The Company has initiated discussions with all note holders regarding maturity date extensions. The Company has not received any notices of default with respect to these notes. Certain notes are accruing interest at the default interest rates even though no notices of default have been received. These notes contain, among other provisions, most favored nation provisions, reserve requirements and default interest rates.</td></tr> </table> Note Payable to SY Corporation Co., Ltd. On June 25, 2012, the Company borrowed 465,000,000 Won (the currency of South Korea, equivalent to $399,774 United States Dollars as of that date) from and executed a secured note payable to SY Corporation Co., Ltd., (“SY Corporation”). The note accrues simple interest at the rate of 12% per annum and had a maturity date of June 25, 2013. The Company has not made any payments on the promissory note. At September 25, 2013 and subsequently, the promissory note was outstanding and in default, although SY Corporation has not issued a notice of default or a demand for repayment. Management believes that SY Corporation is in default of its obligations under its January 2012 license agreement, as amended, with the Company, but the Company has not yet issued a notice of default. The Company has in the past made several efforts towards a comprehensive resolution of the aforementioned matters involving SY Corporation. During the six-months ended June 30, 2023, there were no further communications between the Company and SY Corporation. The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, dating back to January, August and September 2007, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds that the Company is no longer developing and where patent rights date back to January, August and September 2007. The security interest does not extend to the Company’s patents for its AMPAkine compounds CX1739 and CX1942 or certain related method of use patents. <p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_hdei--LegalEntityAxis__custom--SYCorporationMember_zUW2PLKIcl5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The note payable to SY Corporation consists of the following at June 30, 2023 and December 31, 2022: Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230630__dei--LegalEntityAxis__custom--SYCorporationMember_zSyo2RvoNkw3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231__dei--LegalEntityAxis__custom--SYCorporationMember_z9oc9gJMStMe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentFaceAmount_iI_maNPRPCzAYK_zFiUOpSOXpqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Principal amount of note payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">399,774</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">399,774</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_maNPRPCzAYK_zIyhAhqLnvo4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued interest payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,251</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">507,330</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ForeignCurrencyTransactionAdjustment_iNI_di_msNPRPCzAYK_z6UcpOAEbpIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency transaction adjustment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111,287</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NotesPayableCurrent_iTI_mtNPRPCzAYK_zfJLRW3Hq2X8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total note payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">819,738</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">833,463</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Interest expense with respect to this promissory note was $12,092 and $11,960 for the three-months ended June 30, 2023 and 2022, respectively and $23,921 and $23,789 for the six-months ended June 30, 2023 and 2022, respectively. Notes Payable to Officers and Affiliates For the three-months ended June 30, 2023 and 2022, $3,712 and $3,375 was charged to interest expense with respect to Dr. Arnold S. Lippa’s notes, respectively. For the six-months ended June 30, 2023 and 2022, $7,383 and $6,712 was charged to interest expense with respect to Dr. Lippa’s notes, respectively. At June 30, 2023, an affiliate of Dr. Lippa provided $225,000 and was issued a demand promissory note of like amount and warrants as described in more detail below. At June 30, 2023, amounts owed to Dr. Lippa and his affiliates, including notes payable, a demand promissory note, advances and accrued interest were $431,693. In addition, Dr. Lippa periodically makes advances to the Company which are re-payable upon demand, do not accrue interest and are included in the total of notes payable to Officers. On May 22, 2023, RespireRx issued a demand promissory note in the principal amount of $225,000 which bears interest at 10% per year to an affiliate of Dr. Arnold Lippa. In connection with the issuance of the demand promissory note and on the same date, RespireRx issued a Warrant to purchase 75,000,000 shares of the Company’s Common Stock at an exercise price of $0.0015 per share of Common Stock, exercisable at any time until the date that is five years from the initial exercise date of May 22, 2023. The Warrant had a fair value of $112,500 calculated using the Black-Scholes option pricing model utilizing an estimated <span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dxL_c20230522__20230522__srt--TitleOfIndividualAxis__custom--ArnoldLippaMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zOXIw01IO5g1" title="Exercise period in years::XDX::P1Y">one-year volatility calculated based on RespireRx’s historical Common Stock prices, the risk free rate based on U.S Treasury yield curve in effect on the issue date, the exercise period which is this case is <span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dc_c20230522__20230522__srt--TitleOfIndividualAxis__custom--ArnoldLippaMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zmtU5ZMVAo7j" title="Exercise period in years">five years, the fair value of the stock which is considered the closing price on the issue date and the exercise price. The calculated value was charged to interest expense as it is required to be amortized over the life of the note and the note is payable on demand. The Warrant also has cashless exercise provisions. Coupon interest of $2,404 for the period from May 22, 2023 to June 30, 2023 was charged to interest expense for the three-month period and six-month period ended June 30, 2023. Since neither the demand promissory note nor the Warrant existed during the three-month and six-month periods ended June 30, 2022, no such coupon interest or Warrant value interest was charged to interest expense during those periods. On May 22, 2023, RespireRx issued a demand promissory note in the principal amount of $25,000 which bears interest at 10% per year to an affiliate that is not an officer or director of the Company. In connection with the issuance of the demand promissory note and on the same date, RespireRx issued a Warrant to purchase 8,333,333 shares of the Company’s Common Stock at an exercise price of $0.0015 per share of Common Stock, exercisable at any time until the date that is five years from the initial exercise date of May 22, 2023. The Warrant had a fair value of $12,500 calculated using the Black-Scholes option pricing model utilizing an estimated <span id="xdx_904_eus-gaap--DebtInstrumentTerm_dxL_c20230522__20230522__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zEY5RUiSXvza" title="Exercise period in years::XDX::P1Y">one-year volatility calculated based on RespireRx’s historical Common Stock prices, the risk free rate based on the U.S Treasury yield curve in effect on the issue date, the exercise period which is this case is five years, the fair value of the stock which is considered the closing price on the issue date and the exercise price. The calculated value was charged to interest expense as it is required to be amortized over the life of the note and the note is payable on demand. The Warrant also has cashless exercise provisions. Coupon interest of $267 for the period from May 22, 2023 to June 30, 2023, was charged to interest expense for the three-month period and six-month period ended June 30, 2023. Since neither the demand promissory note nor the Warrant existed during the three-month and six-month periods ended June 30, 2022, no such coupon interest or Warrant value was charged to interest expense during those periods. Notes Payable to Former Officer For the three-months ended June 30, 2023 and 2022, $5,628 and $5,116, respectively, was charged to interest expense with respect to former executive officer, Dr. James S. Manuso’s notes. For the six-months ended June 30, 2023 and 2022, $11,194 and $10,177, respectively, was charged to interest expense with respect to Dr. Manuso’s notes. At June 30, 2023, amounts owed to Dr. Manuso, associated with two notes payable and accrued interest were $<span id="xdx_90B_eus-gaap--OtherLiabilitiesCurrent_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManusoMember_zKDkfeyndVo7" title="Notes payable, advances and accrued interest">236,938. At December 31, 2022, amounts owed to Dr. Manuso with respect to the same two notes were $<span id="xdx_90E_eus-gaap--OtherLiabilitiesCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrManusoMember_zkyoo8OgaXEd" title="Notes payable, advances and accrued interest">225,744. Other Short-Term Notes Payable Other short-term notes payable at June 30, 2023 and December 31, 2022 consisted primarily of premium financing agreements with respect to the Company’s directors and officers liability insurance policies. At June 30, 2023, a premium financing agreement was payable in the initial amount of $96,408 (prior to payment of a deposit of $19,228 which was paid in May 2023), with interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--OtherShortTermNotesPayableMember_zIZbIuiZhHK5" title="Interest rate percentage">8.99% per annum, in nine monthly installments of $8,900. At June 30, 2023 and December 31, 2022, the aggregate amount of the short-term notes payable was $60,483 and $15,847 respectively.

The table below summarizes all convertible notes outstanding as of June 30, 2023. Those with similar characteristics outstanding as of June 30, 2023 are grouped separately. The following abbreviations are used in the column headings: DIC is Debt Issuance Cost, OID is Original Issue Discount, Wts are warrants, CNC is Capitalized Note Cost and BCF is Beneficial Conversion Feature. Also included are repayments by conversion, exchange or otherwise during or prior to the three-month period ended June 30, 2023: Schedule of Convertible Notes Outstanding <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Inception Date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Maturity date</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Original Principal Amount</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Interest rate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Original aggregate DIC, OID, Wts, CNC and BCF</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Cumulative amortization of DIC, OID, Wts, CNC and BCF</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accrued coupon interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Repayment by conversion, increase in principal amount, net where appropriate</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Balance sheet carrying amount at June 30, 2023 inclusive</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">November 5, 2014</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_fMQ_____z4br00lYp0Nf" title="Debt Instrument, Maturity Date">September 15, 20161</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_zKhm98A1ajxf" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z7aWosPqaxk9" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z9LssNJtA6rf" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_zYmyFXdM9PR4" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z9z65wCxDmGk" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Interest Payable">32,649</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_zqEeS7faAVuh" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenMember_z3BOL6okL0K6" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Balance sheet carrying amount">57,649</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">November 5, 2014</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_fMQ_____zfb21Hx7TUPf" title="Debt Instrument, Maturity Date">September 15, 20161</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_z2hJNYsL5rS9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zE2Ty56kJxoj" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_z9lwQ6lgP2hh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_z5YbbUKeYSTf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zw3MYA8xRge9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">32,649</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zE2ByUZkeSrf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenOneMember_zRj5840J0na" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">57,649</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">November 5, 2014</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_fMQ_____zmWVCV33sm2a" title="Debt Instrument, Maturity Date">September 15, 20161</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zCQeVj9XQz17" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zkikgvaDsSF" title="Debt Instrument, Interest Rate, Stated Percentage">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_z2fTMZKhgV37" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zBjGf7kyRac3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zzZ9b9DTMgX9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">42,443</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zJb2uogjUqNl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--NovemberFiveTwoThousandAndFourteenTwoMember_zZTTeJMJMoc4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">67,443</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Sub-total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zIg7eZFQyPe5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Sub-total">75,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_ztYy0TdGUTfg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zXNdiWggz259" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_z5SMIVA6tvXf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">107,741</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zMra7ZkyrR06" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableOneMember_zF4IcwnbdIk9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">182,741</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 31, 2018</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_fMg_____zKtsnQUaY2Z5" title="Debt Instrument, Maturity Date">February 28, 20192</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zGXjomrBUf2h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">25,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_z0p9mAhvpkB" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zRzW7HT2LWsd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zXAPmTf8B2Gh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zYB3PX7pl4N3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">14,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_z7dLhtpIOj66" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberThirtyOneAndTwoThousandAndEighteenMember_zVERJ3sb0lxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">39,068</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">January 2, 2019</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_fMg_____zPL7xHdddV2e" title="Debt Instrument, Maturity Date">February 28, 20192</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_z33AimR5RC1j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zrUTxzJ7Rl5e" title="Debt Instrument, Interest Rate, Stated Percentage">10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zNOpOKs0bCk5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zwP1tnwJvl92" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zM1A3Y2KqpM4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">5,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zB2r6p2yH5Ne" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JanuaryTwoTwoThousandAndNineteenMember_zitjM7ebDRL8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">15,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">Sub-total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zvAbu6b5Wpm6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original principal amount sub-total">35,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zMECuiBMATm1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zqzGUQhCXVZf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_z6YQL11D8vFl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">19,695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zAu8d2sicpe9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableTwoMember_zPFIzoCt2V65" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">54,695</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">May 17, 2019</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_fMw_____z4w0vkxjSuQ6" title="Debt Instrument, Maturity Date">May 17, 20203</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zONVn3JIvLb5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_z3IPAQNAhSn9" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zdfLDJn3zuKd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zVXWAyKFPmi3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zP2WsTcNshu8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">5,001</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zAxot2yg3KH8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(52,253</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MaySeventeenTwoThousandAndTwentyMember_zgBBObTkcKoa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">2,748</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">July 28, 2020</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_fMw_____zRpN9NQuHI3e" title="Debt Instrument, Maturity Date">June 30, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zaX9NjTgc9X2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">53,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zSpxX2lr4rT9" title="Debt Instrument, Interest Rate, Stated Percentage">8.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zelUTMpInRf6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(13,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zzQPl0obi0J8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">13,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zasVYXcJ4N7c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">11,196</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_zdp0MMlD5fwk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(16,247</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JulyTwentyEightTwoThousandAndTwentyConvertibleNoteMember_z8gMbYP96E51" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">47,949</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">February 17, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zRUMJpimZyY7" title="Debt Instrument, Maturity Date">June 17, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_znC0CXVzPKhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">112,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zy74vsKzxw37" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_z57iFy8Qg1Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(112,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zMV2iQylinT4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">112,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_znSGKua5YIq1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">13,483</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zPg7pMz02lZ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(80,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--FebruarySeventeenTwoThousandAndTwentyOneConvertibleNoteMember_zKLuzA8PHQz4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">45,483</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">April 1, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____z52sDQpwf41d" title="Debt Instrument, Maturity Date">July 31, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zwySp7FPSzt1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">112,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zxqcFh4Aj4V3" title="Debt Instrument, Interest Rate, Stated Percentage">24.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zH6shNv4dBP8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(112,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zCN0hSz0Anlf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">112,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zJrmF8JcFANh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">67,943</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zkaOUSH6Ub3k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(42,400</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilOneTwoThousandAndTwentyOneConvertibleNoteMember_zfacSaKRTdDd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">138,043</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">May 3, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zg3iVP9KeZVf" title="Debt Instrument, Maturity Date">July 31, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zgiLZzjGQ7g3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zMXtccQCBMNg" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zifC7kRLZKuj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zbM3GCTm0gN2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_ztHrIkJlewA9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_z7lrhve5lBmi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayThreeTwoThousandAndTwentyOneConvertibleNoteMember_zEjxX6rxosr6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">May 10, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zl2JFI09VRF1" title="Debt Instrument, Maturity Date">August 10, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zwaGJm53IZVc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zBgox7Gnultc" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_ze0GXwjA5mol" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zG3ltf7OL8Sc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_z9ehi1p0stbi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">27,185</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zWtlEHbRttea" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(13,213</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--MayTenTwoThousandAndTwentyOneConvertibleNoteMember_zAfAuaDA9J99" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">163,972</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">June 30, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____zCMjLj95dRek" title="Debt Instrument, Maturity Date">June 29, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zjO4MSZXFqi5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zrRvz4frO3c6" title="Debt Instrument, Interest Rate, Stated Percentage">24.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zybzGWRgLbK7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zpZkO7UMErJj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zd8ZV9a9LiH7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">35,073</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zEskUa4fXV7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--JuneThirtyTwoThousandAndTwentyOneConvertibleNoteMember_zCtwGyP7yobh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">150,073</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_fMw_____z5WN2Wr6wfN5" title="Debt Instrument, Maturity Date">August 31, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zwP55t4t30T3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zPwV8sFFZPok" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zqLXcfO1wHVg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(109,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zaWqe8k5xvT7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">109,675</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zCMHKKuVgX9a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">21,047</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zHVXeZ0ZGQ39" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustThirtyOneTwoThousandAndTwentyOneConvertibleNoteMember_zZgOiBAP6k6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">136,047</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">October 7, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_fMw_____z6bqGeb6eBW9" title="Debt Instrument, Maturity Date">October 7, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zMhheuhAqDC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">115,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_z0Byud9O4oN5" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zKyW12nWPZEi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(96,705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zG8yZV9fr6j3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">96,705</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_za0E1kFwHwWe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">19,881</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zvLcPQya8Xjh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OctoberSevenTwoThousandTwentyOneMember_zuAXDf76TARa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">134,881</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">December 23, 2021</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_fMw_____zhlLZMkP8Tja" title="Debt Instrument, Maturity Date">June 21, 20223</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zUq5DcsjEf6h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Instrument, Face Amount">87,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zYcM9XG35VMb" title="Debt Instrument, Interest Rate, Stated Percentage">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zasLj1b6iCO3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(36,301</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_ztAS9M0bxV9k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">36,301</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_z3pQwJVf7I21" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">40,810</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zlL4f0xblNw6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">(23,160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--DecemberTwentyThreeTwoThousandOneMember_zSjU6zNMBRgk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">104,650</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">April 14, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_fMw_____zMWAD3E7Tdnj" title="Debt instrument, maturity date">April 14, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_z93N3U5wHk7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">27,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_z7J33CdEre65" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zl0mEHvc1X13" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(15,936</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zfc1W0i5vRu2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">15,936</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zlSlL8S03Ajd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">3,364</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_zRVWgWpIZvs5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AprilFourteenTwoThousandTwentyTwoMember_z0lHHTdCHe8l" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">31,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 22, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_fMw_____zx2GZSB6DtB7" title="Debt instrument, maturity date">May 31, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zUjoZoYgfDal" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">66,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zDvg06FtT115" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zI1CngbaAR7k" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(6,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zGOW3IBPD862" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">6,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zTBSgXHj3Wqd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">5,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zVLj68adP6ke" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteOneMember_zSGACB8IJ2Wf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">72,366</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 22, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_fMw_____zBZ8pdwIKO3j" title="Debt instrument, maturity date">May 31, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zrOkQSwuOmVd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">22,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zrDtC27oEGBj" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zE9sCjYXxLzh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(2,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_z0QPsUCKMlw8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">2,222</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zGyHBB4daqzg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">1,900</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zawm6eGHRcok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteTwoMember_zqQh6CeXP2J1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">24,122</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">August 22, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_fMw_____zAQmk6XmbpM4" title="Debt instrument, maturity date">May 31, 20233</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zQo9mhoTjjxj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">16,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zzbhrsR53rYc" title="Interest rate">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zAqzI5BRr52h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt Conversion, Original Debt, Amount">(1,667</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zUvRP9Mw9xHh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization">1,434</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zOTnbCgYAWh8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Interest Payable">1,009</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_zEYqo6AQzCJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayments of Convertible Debt">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwoTwoThousandAndTwentyTwoConvertibleNoteThreeMember_z2Awg16Q0ZK2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount">943</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Sub-total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zcoN6Tmpuok4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original principal amount sub-total">1,192,834</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zomvPyGbE227" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original aggregate sub-total">(971,673</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zNZMbGZglzBc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization of DIC, OID, Wts, CS and BCF sub-total">971,440</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zfERCwsIKhC6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued coupon interest sub-total">253,590</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_zxL3eClU8QZ7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayment by conversion sub-total">(393,773</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesPayableThreeMember_z8nb6spBqmsk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Sub-total">1,052,418</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zgpsLxKA1Glk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original Principal Amount">1,302,834</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtConversionOriginalDebtAmount1_iN_di_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zqAnTAOHMpjj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Original aggregate DIC, OID, Wts, CNC and BCF">(971,673</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--AmortizationOfFinancingCosts_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zrXPR9GKasOk" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Cumulative amortization of DIC, OID, Wts, CS and BCF">971,440</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zws3GeZ6acL6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued coupon interest">381,026</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zV8GaYsXjwib" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Repayment by conversion">(393,773</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z75ZDfRmZhGf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Balance sheet carrying amount inclusive of accrued interest">1,289,854</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td id="xdx_F04_zZMjuug3tUJc" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These convertible notes were sold to investors in 2014 and 2015 (“Original Convertible Notes) and have a fixed interest rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_zF7mEnrx4OQh" title="Fixed interest rate">10% per annum and in the case of the one note for which a notice of default has been received, 12%. The Original Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events and are convertible into an aggregate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_z6dHUIcBxCZ2" title="Conversion of common stock">1,560 shares of Common Stock as of June 30, 2023. As of June 30, 2023, principal and accrued interest on the Original Convertible Note that is subject to a default notice totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_z94fIyjm9qf5" title="Convertible notes">67,443, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--OriginalConvertibleNotesMember_zd5x4azwPjVi" title="Accrued interest">42,443 was accrued interest.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_F0C_zEupfdaCBlbj" style="font: 10pt Times New Roman, Times, Serif">2</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 31, 2018 and January 2, 2019, the Company issued convertible notes to a single investor totaling $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90C_eus-gaap--ConvertibleDebt_iI_c20230630__srt--TitleOfIndividualAxis__custom--SingleInvestorMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_zUvHdOjAFi7a" title="Convertible notes">35,000 of maturity amount with accrued interest of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20230630__srt--TitleOfIndividualAxis__custom--SingleInvestorMember__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember_z2jR0UJU2K7g" title="Accrued interest">19,695 as of June 30, 2023. The number of shares of common stock (or preferred stock) into which these notes may convert is not determinable.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_F0A_zoQlS0lnG5od" style="font: 10pt Times New Roman, Times, Serif">3</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These fourteen convertible notes were issued between May 17, 2019 and August 22, 2022. They all currently have similar terms including conversion prices that generally are or are likely to be $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIENvbnZlcnRpYmxlIE5vdGVzIE91dHN0YW5kaW5nIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20230630__us-gaap--DebtInstrumentAxis__custom--FourteenConvertibleNotesMember_zcDTv2LKuTSa" title="Common stock, per share">0.0015 per share of Common Stock. All such notes matured prior to June 30, 2023. The Company has initiated discussions with all note holders regarding maturity date extensions. The Company has not received any notices of default with respect to these notes. Certain notes are accruing interest at the default interest rates even though no notices of default have been received. These notes contain, among other provisions, most favored nation provisions, reserve requirements and default interest rates.</td></tr> </table>

2016-09-15

25000

0.10

32649

57649

2016-09-15

25000

0.10

32649

57649

2016-09-15

25000

0.12

42443

67443

75000

107741

182741

2019-02-28

25000

0.10

14068

39068

2019-02-28

10000

0.10

5627

15627

35000

19695

54695

2020-05-17

50000

0.1000

50000

5001

-52253

2748

2022-06-30

53000

0.0800

13000

11196

-16247

47949

2022-06-17

112000

0.1000

112000

13483

-80000

45483

2022-07-31

112500

0.2400

112500

67943

-42400

138043

2022-07-31

150000

0.1000

150000

-150000

2022-08-10

150000

0.1000

150000

27185

-13213

163972

2022-06-29

115000

0.2400

115000

35073

150073

2022-08-31

115000

0.1000

109675

21047

136047

2022-10-07

115000

0.1000

96705

19881

134881

2022-06-21

87000

0.1000

36301

40810

-23160

104650

2023-04-14

27778

0.1000

15936

3364

31142

2023-05-31

66667

0.1000

6667

5699

72366

2023-05-31

22222

0.1000

2222

1900

24122

2023-05-31

16667

0.1000

1667

1434

1009

943

1192834

971673

971440

253590

-393773

1052418

1302834

971673

971440

381026

-393773

1289854

0.10

1560

67443

42443

35000

19695

0.0015

465000000

399774

0.12

<p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_hdei--LegalEntityAxis__custom--SYCorporationMember_zUW2PLKIcl5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The note payable to SY Corporation consists of the following at June 30, 2023 and December 31, 2022: Schedule of Convertible Notes Payable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20230630__dei--LegalEntityAxis__custom--SYCorporationMember_zSyo2RvoNkw3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231__dei--LegalEntityAxis__custom--SYCorporationMember_z9oc9gJMStMe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentFaceAmount_iI_maNPRPCzAYK_zFiUOpSOXpqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Principal amount of note payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">399,774</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">399,774</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestPayableCurrent_iI_maNPRPCzAYK_zIyhAhqLnvo4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued interest payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,251</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">507,330</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ForeignCurrencyTransactionAdjustment_iNI_di_msNPRPCzAYK_z6UcpOAEbpIl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency transaction adjustment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111,287</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NotesPayableCurrent_iTI_mtNPRPCzAYK_zfJLRW3Hq2X8" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total note payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">819,738</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">833,463</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

399774

531251

507330

111287 73641

819738

833463

12092

11960

23921

23789

3712

3375

7383

6712

225000

431693

225000

0.10

75000000

0.0015

112500

P5Y

2404

25000

0.10

8333333

0.0015

12500

P5Y

267

5628

5116

11194

10177

236938

225744

96408

19228

0.0899

8900

60483

15847

5. Settlement and Payment Agreements Effective December 15, 2022, the Company and the Board of Trustees of the University of Illinois (“UIL”) entered into the Second Amendment to RespireRx -University of Illinois Exclusive License Agreement. The parties entered into the Second Amendment in order to eliminate accrued financial obligations to UIL and reduce future obligations. Annual $100,000 payments by the Company to UIL were eliminated and the unpaid amounts totaling $200,000 for calendar years 2021 and 2022 are no longer due and payable. Among other changes, the $75,000 payment that was due after the dosing of the 1st patient in a Phase II study anywhere in the world is now reduced to $10,000 and UIL has been given an extension in the term of the License and a deferred compensation obligation of RespireRx including the 4% royalty on net sales due to UIL has been extended for up to 8 years after the original patent rights expire by including a royalty on the net sales protected by a patent application submitted by the Company describing a new formulation of dronabinol. On August 3, 2023, the 2014 License Agreement inclusive of both amendments was sublicenced to RespireRx’s wholly-owned subsidiary, ResolutionRx. See Note 8. Commitments and Contingencies-Significant Agreements and Contracts-University of Illinois Exclusive License Agreement for more details. Effective August 1, 2022, the Company and the Company’s former legal counsel, entered into a payment settlement agreement and release pursuant to which the Company and its former legal counsel agreed that the Company owed $<span id="xdx_907_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20220801__srt--TitleOfIndividualAxis__custom--FormerLegalCounselMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zE8YUt7jPJvf" title="Investment owned, face amount">2,608,914 to such counsel and that under the terms of the agreement the amount owed and payable by wire transfer on or before December 30, 2022 was $<span id="xdx_902_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20221230__srt--TitleOfIndividualAxis__custom--FormerLegalCounselMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zGaLu1mctvc4" title="Investment owned, face amount">250,000. If that amount was paid on or before December 30, 2022, certain mutual releases would become effective and no further amounts would be due. If the $<span id="xdx_907_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20221230__srt--TitleOfIndividualAxis__custom--FormerLegalCounselMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zCEGiOnEb7t7" title="Investment owned, face amount">250,000 amount was not paid by December 30, 2022, the section of the agreement related to mutual releases would be null and void ab initio and the amount immediately due and payable by the Company to its former counsel would be adjusted to $<span id="xdx_902_eus-gaap--InvestmentOwnedUnderlyingFaceAmountAtMarketValue_iI_c20220801__srt--TitleOfIndividualAxis__custom--FormerLegalCounselMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zZ52CFDvRQej" title="Investment owned, face amount">2,608,914 less any amounts paid on or after the date of the agreement. The amount due by December 30, 2022 was not paid and the payment settlement agreement was amended to call for a payment of $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20230215__srt--TitleOfIndividualAxis__custom--FormerLegalCounselMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zq14fxvHWQGa" title="Notes payable">350,000 by February 15, 2023, which amount was also not paid. The Company and its former legal counsel are in discussions regarding further revised payment settlement terms. The amount due to the Company and its former legal counsel included in accounts payable as of June 30, 2023 is $<span id="xdx_90C_eus-gaap--AccountsPayableCurrent_iI_c20230630__srt--TitleOfIndividualAxis__custom--FormerLegalCounselMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zZPjf7EzdML8" title="Accounts payable">2,608,914. Effective January 31, 2022, the Company’s former President and Chief Executive Officer and Member of the Board of Directors, Timothy Jones, resigned his officer positions as well as from the Board of Directors pursuant to an Employment Agreement Termination and Separation Agreement (“SA”) dated February 8, 2022. Pursuant to the terms of the SA, the Company has agreed to pay Mr. Jones up to a maximum of $789,267 in accordance with a schedule set forth in the SA based on amounts of funding raised by the Company, all in payment for Mr. Jones’ service to the Company as President and Chief Executive Officer prior to January 31, 2022. All such amounts are included in accrued compensation as of June 30, 2023 and December 31, 2022. Mr. Jones did not resign because of any disagreement with the Company relating to the Company’s operations, policies or practices. On April 29, 2021, RespireRx agreed to a payment and settlement agreement with the University of California Innovation and Entrepreneurship (“UIC”) with respect to accounts payable in an amount that was not in dispute and is reflected in accounts payable and accrued expenses in the Company’s condensed consolidated financial statements as of December 31, 2022 and June 30, 2023. The total amount due was $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20210429__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--PaymentandSettlementAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--UniversityofCaliforniaInnovationandEntrepreneurshipMember_zBc39Ih01jti" title="Notes payable">234,657. The agreed payment schedule is for the Company to pay $<span id="xdx_90B_ecustom--AgreedPaymentValue_iI_c20210429__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--PaymentandSettlementAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--UniversityofCaliforniaInnovationandEntrepreneurshipMember_znvYiVfCrDll" title="Agreed payment value">10,000 on each of July 1, 2021, September 1, 2021, November 1, 2021, January 1, 2022 and March 31, 2022. If RespireRx paid an aggregate of $<span id="xdx_909_eus-gaap--NotesPayable_iI_c20220331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--PaymentandSettlementAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--UniversityofCaliforniaInnovationandEntrepreneurshipMember_zJh9b2bLlyz5" title="Notes payable">175,000 on or before March 31, 2022, the amounts would have been considered paid in full with no further amounts due. RespireRx has not made any payments after the September, 2021 payment. According to the terms of the agreement, if an aggregate of $<span id="xdx_90E_eus-gaap--NotesPayable_iI_c20220331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--PaymentandSettlementAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--UniversityofCaliforniaInnovationandEntrepreneurshipMember_zKML3j5F66N7" title="Notes payable">175,000 was not paid by March 31, 2022, the remaining unpaid amount up to an aggregate of the original amount of $<span id="xdx_909_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20230630__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--PaymentandSettlementAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--UniversityofCaliforniaInnovationandEntrepreneurshipMember_zm3cFURDLlE7" title="Accounts payable">234,657 less any payments previously made would be due and payable. Payment was not made and the original amount of $<span id="xdx_90E_eus-gaap--ProceedsFromShortTermDebt_c20230101__20230331__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--TypeOfArrangementAxis__custom--PaymentandSettlementAgreementMember__us-gaap--RelatedPartyTransactionAxis__custom--UniversityofCaliforniaInnovationandEntrepreneurshipMember_zku1ZS6AVweb" title="Payment of debt">234,657 less the payments made up to September, 2021 have been recorded in accounts payable at June 30, 2023. The Company remains in discussions with an agent on behalf of UIC to establish a new payment settlement schedule. On February 21, 2020, Sharp Clinical Services, Inc. (“Sharp”), a vendor of the Company, filed a complaint against the Company in the Superior Court of New Jersey Law Division, Bergen County related to a December 16, 2019 demand for payment of past due invoices inclusive of late fees totaling $103,890. On May 29, 2020, a default was entered against the Company, and on September 4, 2020, a final judgment was entered against the Company in the amount of $104,217. On March 3, 2021, we executed a settlement agreement with Sharp (the “Sharp Settlement Agreement”), and on March 9, 2021, Sharp requested of the Bergen (NJ) County Sheriff, the return of the Writ of Execution which resulted in a release of the lien in favor of Sharp. The Sharp Settlement Agreement calls for a payment schedule of ten $10,000 payments due on April 1, 2021 and every other month thereafter, and permitted early settlement at $75,000 if the Company had paid Sharp that lower total by August 1, 2021. The Company did not pay Sharp that lower amount by that date. The Company has recorded a liability to Sharp of $<span id="xdx_902_eus-gaap--OtherLiabilitiesCurrent_iI_c20230331__dei--LegalEntityAxis__custom--SharpClinicalServicesIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWpuPducobWk" title="Due to related parties, current">53,568 as of June 30, 2023 after payments totaling $30,000 pursuant to the Sharp Settlement Agreement in August, October and December 2021. The Company has not made the any of the payments due on or after October 1, 2021. On March 3, 2022, Company’s then counsel received a default notice from counsel to Sharp with respect to the Sharp Settlement Agreement, which stated that Sharp may exercise its remedies. Company’s then counsel communicated with counsel to Sharp. On March 28, 2022, one of the Company’s bank accounts was debited $415 inclusive of fees for the benefit of Sharp. By letter dated February 5, 2016, the Company received a demand from a law firm representing Salamandra, LLC (“Salamandra”) alleging an amount due and owing for unpaid services rendered. On January 18, 2017, following an arbitration proceeding, an arbitrator awarded Salamandra the full amount sought in arbitration of $<span id="xdx_903_eus-gaap--OtherLiabilitiesCurrent_iI_c20170118__dei--LegalEntityAxis__custom--SalamandraLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zMlaPdm62m77" title="Due to related parties, current">146,082. Additionally, the arbitrator granted Salamandra attorneys’ fees and costs of $47,937. All such amounts have been accrued as of June 30, 2023, including accrued interest at 4.5% annually from February 26, 2018, the date of the judgment, through June 30, 2023, totaling $43,376. The Company had previously entered into a settlement agreement with Salamandra that is no longer in effect. The Company believes that a lien with respect to the amounts owed is in effect. On September 14, 2021, the Company and DNA Healthlink, Inc. (“DNA Healthlink”) entered into a settlement agreement (the “DNA Healthlink Settlement Agreement”) regarding $<span id="xdx_909_eus-gaap--AccountsPayableTradeCurrent_iI_c20210914__dei--LegalEntityAxis__custom--DNAHealthlinkIncMember__us-gaap--TypeOfArrangementAxis__custom--DNAHealthlinkSettlementAgreementMember_z1yeMQp8BgTl">410,000 in unpaid accounts payable owed by the Company to DNA Healthlink (the “DNA Healthlink Settlement Amount”) for services provided by DNA Healthlink to the Company pursuant to an agreement by and between the Company and DNA Healthlink dated October 15, 2014. Under the terms of the DNA Healthlink Settlement Agreement, the Company is obligated to pay to DNA Healthlink the full DNA Healthlink Settlement Amount as follows: twelve monthly payments of $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20210913__20210914__dei--LegalEntityAxis__custom--DNAHealthlinkIncMember__us-gaap--TypeOfArrangementAxis__custom--DNAHealthlinkSettlementAgreementMember__us-gaap--AwardDateAxis__custom--NovemberFifteeenTwoThousandAndTwentyOneMember_z0JvxgStMv1j">8,000 commenced on November 15, 2021, followed by twelve monthly payments of $<span id="xdx_90D_eus-gaap--DebtInstrumentPeriodicPayment_c20210913__20210914__dei--LegalEntityAxis__custom--DNAHealthlinkIncMember__us-gaap--TypeOfArrangementAxis__custom--DNAHealthlinkSettlementAgreementMember__us-gaap--AwardDateAxis__custom--NovemberFifteeenTwoThousandAndTwentyTwoMember_zJywdfboUGOg">10,000 which commenced on November 15, 2022, followed by twelve monthly payments of $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_c20210913__20210914__dei--LegalEntityAxis__custom--DNAHealthlinkIncMember__us-gaap--TypeOfArrangementAxis__custom--DNAHealthlinkSettlementAgreementMember__us-gaap--AwardDateAxis__custom--NovemberFifteeenTwoThousandAndTwentyThreeMember_zKhlCQH5wWbg">15,000 commencing on November 15, 2023, followed by one final payment of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_c20210913__20210914__dei--LegalEntityAxis__custom--DNAHealthlinkIncMember__us-gaap--TypeOfArrangementAxis__custom--DNAHealthlinkSettlementAgreementMember__us-gaap--AwardDateAxis__custom--NovemberFifteeenTwoThousandAndTwentyFourMember_zpMuxdqemaoh">14,000 on November 15, 2024. If, prior to March 14, 2023, the Company had received one or more upfront license fee payments or any other similar fee or fees from one or more strategic partners that aggregate at least fifteen million dollars ($<span id="xdx_909_eus-gaap--PaymentsForFees_pp2d_c20230313__20230314__dei--LegalEntityAxis__custom--DNAHealthlinkIncMember__us-gaap--DebtInstrumentAxis__custom--UpfrontFeesMember__us-gaap--TypeOfArrangementAxis__custom--DNAHealthlinkSettlementAgreementMember_zTWXbhytXdcj">15,000,000.00) (“Upfront Fees”), then the full DNA Healthlink Settlement Amount, less any amounts previously paid, would have been accelerated and become due and payable in full within ninety (90) days of receipt of any Upfront Fees. The Company made payments of $8,000 in November 2021 and December 2021, but has not made payments thereafter. Of the $390,000 total amount due, $74,000 has been reflected as long-term liabilities and the remaining amount has been reflected in accounts payable and accrued expenses in the Company’s condensed consolidated balance sheet as of June 30, 2023. By email dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company in 2012 in conjunction with the Pier transaction alleging that $225,000 is due and payable for investment banking services rendered. Such amount has been included in accrued expenses at June 30, 2023 and December 31, 2022. The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed consolidated financial statements as of June 30, 2023 and consolidated financial statements as of December 31, 2022 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously defend itself if any of the matters described above results in the filing of a lawsuit or formal claim.

100000

200000

75000

10000

0.04

2608914

250000

2608914

350000

2608914

789267

234657

10000

175000

234657

103890

104217

10000

75000

53568

30000

415

146082

47937 0.045 43376

410000

8000

10000

15000

14000

15000000.00

8000

390000

74000

225000

6. Stockholders’ Deficiency Preferred Stock RespireRx has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share. As of June 30, 2023 and December 31, 2022, <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zMhPUgkEIiH4" title="Preferred stock shares authorised">37,500 shares were designated as Series B Convertible Preferred Stock (non-voting, “Series B Preferred Stock”). Series B Preferred Stock outstanding as of June 30, 2023 and December 31, 2022 consisted of <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayOneThousandNineHundredNinetyOneMember_zpnF7bNBEAQa"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--MayOneThousandNineHundredNinetyOneMember_zljF5gAjEmHh">37,500 shares issued in a May 1991 private placement. The shares of Series B Preferred Stock are convertible into 1 share of common stock. RespireRx may redeem the Series B Preferred Stock for $<span id="xdx_906_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBhZDoRRk5ok" title="Preferred stock liquidation preference value">25,001 at any time upon 30 days prior notice. As of June 30, 2023, there were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zdW9mG6B7oKl" title="Number of shares available for issuance">1,376 shares of Series H Preferred Stock designated and available for issuance. On April 3, 2023, RespireRx authorized 3,500 shares of Series I 8% Redeemable Preferred Stock (“Series I Preferred Shares”), par value $0.001 and stated value $100.00. The Series I Preferred Shares pay an 8% dividend in-kind, are non-voting, redeemable and non-convertible. The Series I Preferred Stock is redeemable upon the occurrence of certain event(s). The redemption amount which is defined as the Eligible Payment is calculated as the Maximum Appreciated Price (unless a lesser price is agreed by RespireRx and the holder) which is $0.02 multiplied by the number of shares of Common Stock corresponding the number of Series I Preferred Shares divided by the Base Measurement Price of $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230403__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zuhxgub7cAGd" title="Preferred stock value">0.0015 multiplied by the stated amount. An Eligible Payment becomes payable upon the occurrence of an Eligible Payment Event. An Eligible Payment Event is caused by (i) any license, sublicense, joint venture or similar transaction resulting in an upfront payment of at least $15,000,000, or (ii) any milestone payment with respect to research and development of at least $15,000,000, or (iii) receipt of royalties in any one year of at least $15,000,000 or (iv) any event resulting in RespireRx’s receipt of an amount deemed by RespireRx’s Board of Directors to establish an Eligible Payment Event. A Fundamental Event as defined in the Certificate of Designation, Preferences, Rights and Limitations of the Series I 8% Redeemable Preferred Stock may cause an Eligible Payment Event. Series I Preferred Shares have certain restrictions on transfer. Between April 5, 2023 and June 15, 2023, RespireRx sold and issued<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230405__20230615__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zY1yQZoNMPJ4" title="Sale of stock, shares"> 700 Series I Preferred Shares for $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230405__20230615__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zMkQfiVkzDzh" title="Sale of stock, value">70,000 which accrued $<span id="xdx_909_eus-gaap--DividendsPreferredStockPaidinkind_c20230405__20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_z3piRI7DhIe8" title="Preferred stock, dividend paid in kind">891 of dividends in-kind through June 30, 2023, resulting in the issuance of an additional <span id="xdx_90E_ecustom--SharesAdditionallyAvailableForIssuance_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zvGm6EqTiU3k" title="Shares additionally available for issuance">9 Series I Preference Shares. Therefore, as of June 30, 2023, there were 709 Series I Preferred Shares outstanding and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesIPreferredStockMember_zsskcPx4ThF" title="Shares available for issuance">2,791 Series I Preferred Shares available for issuance. On April 12, 2023, RespireRx authorized 15,000 shares of Series J 8%Voting, Participating, Redeemable Preferred Stock (“Series J Preferred Shares”), par value $0.001 and stated value $100.00. The Series J Preferred Shares pay an 8% dividend in-kind, are voting, participating, redeemable and non-convertible. The Series J Preferred Stock is redeemable upon the occurrence of certain event(s). The redemption amount which is defined as the Eligible Payment is calculated as the Maximum Appreciated Price (which is the closing price per share of RespireRx’s Common Stock or its equivalent on the date that is the Trading Day on which the Eligible Payment Event is publicly announced prior to the opening of the financial markets on such date, or the Trading Day following the public announcement of the Eligible Payment Event if announced after the opening of the financial markets on the date of the Eligible Payment Event) multiplied by the number of shares of Common Stock corresponding to the number of Series J Preferred Shares divided by the Base Measurement Price of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20230412__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zVsRmgDDEQCg" title="Preferred stock value">0.006 multiplied by the stated value. An Eligible Payment becomes payable upon the occurrence of an Eligible Payment Event. An Eligible Payment Event is caused by (i) any license, sublicense, joint venture or similar transaction resulting in an upfront payment of at least $20,000,000, or (ii) any milestone payment with respect to research and development of at least $20,000,000, or (iii) receipt of royalties in any one year of at least $20,000,000 or (iv) any event resulting in RespireRx’s receipt of an amount deemed by the Corporation’s Board of Directors to establish an Eligible Payment Event. A Fundamental Event as defined in the Certificate of Designation, Preferences, Rights and Limitations of the Series J 8% Redeemable Preferred Stock may cause an Eligible Payment Event. Series J Preferred Shares have certain restrictions on transfer. On April 12, 2023, in connection with the signing of one Exchange Agreement and two Exchange and Settlement Agreements with two executive officers of RespireRx who are also directors and one vendor who is an affiliate, (collectively the “Exchangers”), the Exchangers exchanged $570,000 of accrued compensation or other liabilities owed to them for 5,700 Series J Preferred Shares and immediately completed permitted transfers of such shares to family trusts or affiliates and which shares accrued dividends of $9,870 from April 12, 2023 to June 30, 2023 resulting in the issuance of an additional 99 shares of Series J Preferred Stock. Therefore, as of June 30, 2023, there were 5,799 Series J Preferred Shares issued and outstanding and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230630__us-gaap--StatementClassOfStockAxis__custom--SeriesJPreferredStockMember_zcoUJLgMMvp5" title="Preferred stock shares">9,201 Series J Preferred Shares available for issuance. No gain or loss was recorded on the exchange and settlement of the accrued compensation or other liabilities for the Series J Preferred Shares issued. Although other series of preferred stock have been designated, no other shares of preferred stock are outstanding. As of June 30, 2023, 3,485,924 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate. As of December 31, 2022, 3,504,424 shares of preferred stock were undesignated. Common Stock RespireRx has authorized 2,000,000,000 shares of Common Stock, par value $0.001 (“Common Stock”). There are 220,728,647 shares of RespireRx’s Common Stock outstanding as of June 30, 2023. The issued and outstanding shares of Common Stock as of June 30, 2023 included 56,039,999 shares of Common Stock issued upon conversion of convertible notes and 39,144,372 shares of Common Stock issued upon cashless exercise of warrants during the six-month period ended June 30, 2023. After reserving for conversions of convertible debt and convertible preferred stock, as well as exercises of common stock purchase options (granted and available for grant within the 2014 and 2015 stock and stock option plans) and warrants and the issuance of Pier contingent shares and before accounting for incremental contract excess reserves, there were 642,219,502 shares of RespireRx’s Common Stock available for future issuances as of June 30, 2023. No options were exercised during the six-month period ended June 30, 2023. Options exercisable into <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20230630__us-gaap--AwardTypeAxis__custom--InTheMoneyCommonStockWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFXtwOsKzAQ6">31,019 shares of Common Stock expired during the six-month period ended June 30, 2023. During the three-month and six-month periods ended June 30, 2023, warrants exercisable into <span id="xdx_90D_ecustom--Warrantsexercisable_iI_c20230630__us-gaap--AwardTypeAxis__custom--InTheMoneyCommonStockWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zr2Xii4ZSujc">25,500,000 and a total of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20230630__us-gaap--AwardTypeAxis__custom--InTheMoneyCommonStockWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5vRr22ELGU5">49,800,000 shares of Common Stock if exercised on a cash basis were exercised on a cashless basis resulting in the issuance of 20,361,976 shares of Common Stock during the three-month period ended June 30, 2023 and a total of 39,144,372 for the six-month period ended June 30, 2023. Warrants exercisable into <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZyJ9q039DZ9">23,881 shares of Common Stock expired during the six-month period ended June 30, 2023. No options or warrants were exercised after June 30, 2023. After June 30, 2023, three convertible note holders of notes with substantially similar attributes converted $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230701__20230821__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrTAMIPom1qb" title="Debt instrument, Principal amount">65,753 of principal, $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPaymentInterest_c20230701__20230821__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZYq55HliIJ6" title="Debt instrument, interest amount">747 of interest, $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20230701__20230821__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRjnypvA0hLj" title="Conversion fees">1,000 of conversion fees for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_c20230701__20230821__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zE3Mk4dHxlta" title="Common stock, conversion units value">67,500, into <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230701__20230821__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6sb1jXpOlCc" title="Common stock, conversion units shares">45,000,000 shares of Common Stock at a conversion price, in each case of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230821__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zICa1JxnEg56" title="Conversion price">0.0015 per share of Common Stock. Common Stock Warrants <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-IENE_zms9UHtgo3Uj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of warrant activity for the six-months ended June 30, 2023 is presented below. Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Number of Shares</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Weighted Average Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Weighted Average Remaining Contractual Life (in Years)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 55%">Warrants outstanding and exercisable at December 31, 2022</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230630_zMZw3Q4hP7Z6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares Warrants, outstanding, Beginning balance">419,683,183</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iS_c20230101__20230630_z4IFuAp4Pqfl" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">0.0074</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_z4XkNTLsdecf" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">3.28</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20230630_z18bbIM8xi8g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares. Warrants Exercised">(49,800,000</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssuedExercised_c20230101__20230630_z8GTWWulxtV3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Exercised">0.0015</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Issued</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230630_z4vABa4IrXNk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Issued">83,333,333</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued_c20230101__20230630_z9zYUxZ92sb7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Issued">0.0015</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualIssued_dtY_c20230101__20230630_z0gmXXaAlmKg" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">4.90 </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_iN_di_c20230101__20230630_zOA2OgPNbeic" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired">(23,881</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired_c20230101__20230630_z5cjtE0ZC3fe" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Expired">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants outstanding and exercisable at June 30, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230630_zNnQH0orWST5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares Warrants, outstanding, Ending balance">453,192,635</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iE_c20230101__20230630_zvgJ1aokkG81" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">0.0060</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630_zEqA93eMQ6jk" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">3.27</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_898_ecustom--ScheduleOfExercisePricesOfCommonStockWarrantsOutstandingAndExercisableTableTextBlock_gL3SOEPOCSWOA-VR_z50DSgUYoXVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2023: Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Warrants Outstanding and Exercisable (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Dates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztPFh43waUGj" style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: right" title="Warrants, Exercise Price">0.0015</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbtKIjZEGlq8" style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">427,415,641</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zCY4pBx2LKzi">September 30, 2023-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zsf02WbSUa7f">May 22, 2028</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z37J9lJ9Utpf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0389</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaRTwq7CS8d9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">208,227</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztKKUoxwzfLh">May 10, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGZLWh36Sgij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0470</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zha261onpcYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">172,341</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDL90CCuml7f">May 3, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPQF9d9yQThd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0700</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhAaeevzEhN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">25,377,426</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOPmHYYQUH42">September 30, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">$</td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyRaYBuyJgXj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Warrants, Exercise Price">15.0000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZuXhDPBDtD5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">19,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ZnEL7MWof8">December 30, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztuxXf3JKfZd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">453,192,635</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> Based on a value of $0.0015 per share on June 30, 2023, there were <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20230630__us-gaap--AwardTypeAxis__custom--InTheMoneyCommonStockWarrantsMember_zDRwvuAX0X03" title="Warrants exercised">427,415,641 exercisable at-the-money common stock warrants as of June 30, 2023. <div id="xdx_C0E_gL3SOSENWORTB-IENE_zmEFHoZf8Gaj">A summary of warrant activity for the six-months ended June 30, 2022 is presented below. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%">Warrants outstanding at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220630_zXKLgjEozvi5" style="width: 12%; text-align: right" title="Number of Shares, Warrants outstanding, Beginning balance">59,420,298</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iS_c20220101__20220630_zhKb4SpuxHZ3" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">0.0718</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zhF0Bxk9Ccz5" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">3.3300</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issued as a result of most favored nation provisions</td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220630_zdnfxirX2iTj" style="text-align: right" title="Number of Shares, Warrants Issued">36,102,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued_c20220101__20220630_zEILCTjVbffi" style="text-align: right" title="Weighted Average Exercise Price, Warrants Issued">0.0100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualIssued_dtY_c20220101__20220630_zUniO4Z4Zj6b" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">4.2976</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20220630_zZcmKOXFpKP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Expired">(2,212,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired_c20220101__20220630_z7MskphIh9Sf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Expired">0.0160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable at June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220630_zNWPToArn8Z5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants outstanding, Ending balance">93,310,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iE_c20220101__20220630_z2rXGjvMfsi9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">0.0472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220630_zG2XoLRi9Cg9" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">2.5557</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> The exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2022: <div id="xdx_C0D_gL3SOEPOCSWOA-VR_zVrAicc2qv5i"> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Warrants Outstanding (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Warrants Exercisable (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zg2T20D7h1Gg" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrants, Exercise Price">0.010</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWubTkxPOuvj" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrants, Outstanding (Shares)">67,405,073</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLrIaFwqlHyf" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrants, Exercisable (Shares)">67,405,073</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zlOEzAHGX933" title="Expiration Date">September 30, 2023-<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5RZrSZn4Ldk" title="Expiration Date">April 14, 2027 </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRui7OwNEO4e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0389</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1iZ4miovXn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">208,227</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaHFMr2QEp96" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">208,227</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGACEUg7uJKk" title="Expiration Date">May 10, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6GNgvJPhmD6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.047</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwp58Z0wCFok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">172,341</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMjkFZg4advh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">172,341</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHGvHg987Zf4" title="Expiration Date">May 3, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8qca5ShjxI9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.070</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZBtkasNSbI5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">25,377,426</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5hbVFxeGSA9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">25,377,426</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ4tC3UMwl3a" title="Expiration Date">September 30, 2023</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zTbhoL4cEVqi" title="Warrants, Exercise Price">11.00 -<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z8kgp6YDODO" title="Warrants, Exercise Price">15.750</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYIXeyPYWOgd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">147,531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5jcLfhst5Pb" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">147,531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zHiyuzWXEnG2" title="Expiration Date">September 29, 2022-<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zDT60o8Afrj" title="Expiration Date">December 30, 2023</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeov0aEttrt" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">93,310,598</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3SZRegDZ0e8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">93,310,598</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> </div> Based on a value of $0.0038 per share on June 30, 2022, there were no exercisable in-the-money common stock warrants as of June 30, 2022. Stock Options On March 18, 2014, the stockholders of RespireRx holding a majority of the votes to be cast on the issue approved the adoption of RespireRx’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had been previously adopted by the Board of Directors, subject to stockholder approval. The Plan permits the grant of options and restricted stock in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of RespireRx. As of June 30, 2023, there are <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandFourteenEquityPlanMember_z1HEdOpoSUnl" title="Share based compensation arrangement by share based payment award number of shares available for grant">6,325 share available in the 2014 Plan. The 2014 Plan has provisions for the issuance of stock appreciation rights and phantom stock. On June 7, 2023, phantom stock awards (“Phantom Stock Awards”) totaling <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230607__20230607__us-gaap--PlanNameAxis__custom--TwoThousandFourteenEquityPlanMember_zfwearojKwZb" title="Number of shares, options granted">306,000,000 shares of phantom stock (“Phantom Stock”) were made to certain officer and directors and vendors, consultants and advisors. Shares of phantom stock are not convertible into Common Stock and therefore, no reserves were established for such awards. See Note 8. Commitments and Contingencies-Phantom Stock for a description of the phantom stock awarded on June 7, 2023. On June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (as amended, the “2015 Plan”). As of June 30, 2023, there are <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandFifteenStockAndStockOptionyPlanMember_z5XThG7Flvq3" title="Number of shares, available for grant">13,701,149 shares available in the 2015 Plan. RespireRx has not and does not intend to present the 2015 Plan to stockholders for approval. Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock-based compensation costs and fees is provided at Note 3. <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfrJVxEr3KLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of stock option activity for the six-months ended June 30, 2023 is presented below. Summary of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%">Options outstanding at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630_zC5ptbxO2I39" style="width: 12%; text-align: right" title="Number of Shares, Options outstanding, Beginning balance">9,199,356</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630_zWnNH5V2w5vh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Options outstanding, Beginning balance">0.592</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z3NmtF0xdKEf" title="Weighted Average Remaining Contractual Life, Options outstanding">3.74</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_zCvZNhotovFi" style="text-align: right" title="Number of Shares, Options Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zwrORowl0yG2" style="text-align: right" title="Weighted Average Exercise Price, Options Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230630_zP5Tt8aVgtfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Options Expired">(31,039</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zOyabDPo2448" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Options Expired">11.200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding and exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630_z908LZbhzU31" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options outstanding, Ending balance">9,168,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20230630_zse59s7sJgY1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options outstanding, Ending balance">0.556</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630_zc9VEM2fMrn" title="Weighted Average Remaining Contractual Life, Options outstanding">2.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ziRZbP3ZA2q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2023: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Options Outstanding (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Options Exercisable (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zCqv0n4jbLwc" title="Options Exercise Price">0.0190</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyiMhFBtaxj1" title="Options Outstanding (Shares)">2,194,444</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYSYj3i7WDr8" title="Options Exercisable (Shares)">2,194,444</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_ziVhsNGM6Wn3" title="Options, Expiration Date">December 31, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4aebFeNINwk" title="Options Exercise Price">0.0540</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z88Z8dXDhtRi" title="Options Outstanding (Shares)">1,700,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4moBzvXbFDe" title="Options Exercisable (Shares)">1,700,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z5Ucx1KxIKmf" title="Options, Expiration Date">September 30, 2025</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zf80XwOfan1" title="Options Exercise Price">0.072</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zYMNlXR2Re42" title="Options Outstanding (Shares)">5,050,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zuKAN56nEgSc" title="Options Exercisable (Shares)">5,050,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zaDz77utbtEb" title="Options, Expiration Date">July 31, 2025</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MinimumMember_z5espdr3Iwod" title="Options Exercise Price">7.00-$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MaximumMember_zHKSg0sqEKq4" title="Options Exercise Price">159.25</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zOf5FMkOMXQ3" title="Options Outstanding (Shares)">223,873</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zNtxHhbVPebd" title="Options Exercisable (Shares)">223,873</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MinimumMember_zivqDlNTE5lh" title="Options, Expiration Date">November 21, 2023 - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MaximumMember_zssYZuhJzmy6" title="Options, Expiration Date">December 9, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,168,317</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,168,317</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td></tr> </table> There was no deferred compensation expense as there were no outstanding and unvested stock options at June 30, 2023. Based on a fair value of $0.0015 per share on June 30, 2023, there were no exercisable in-the-money common stock options as of June 30, 2023. Reserved and Unreserved Shares of Common Stock As of June 30, 2023, there are 2,000,000,000 shares of Common Stock, par value $0.001 authorized, of which 220,728,647 are issued and outstanding. As of June 30, 2023, there were outstanding options to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandFourteenEquityPlanMember_z66RSZNCmFu5" title="Options to purchase shares">9,168,317 shares of Common Stock and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230630__us-gaap--PlanNameAxis__custom--TwoThousandFourteenEquityPlanMember_zr4vr6FbQydf" title="Share based compensation arrangement by share based payment award number of shares available for grant">6,325 and <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630__us-gaap--PlanNameAxis__custom--TwoThousandFifteenEquityPlanMember_zN9FTVlnvkHg" title="Number of shares available for issuance">13,701,149 shares available for issuance under the 2014 Plan and 2015 Plan respectively. There are 649 Pier contingent shares of Common Stock that may be issued under certain circumstances. As of June 30, 2023, there are <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_zKO8dLxlYFRg" title="Debt conversion shares issuable">660,982,775 issuable upon conversion of convertible notes. As of June 30, 2023, there are 453,192,635 shares that may be issued upon exercise of outstanding warrants. As of June 30, 2023, the Series B Preferred Stock may convert into 1 share of Common Stock. Therefore, RespireRx is reserving <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhBWVPzu7rV8" title="Common stock available for future issuances">1,114,175,410 shares of Common Stock for future issuances with respect to conversions and exercises as well as for the Pier contingent shares. In addition, certain convertible notes and related warrants impose an additional contractual reserve requirement, above the number of shares into which such convertible notes and related warrants may convert or exercise respectively. Neither the Series I Preferred Shares nor the Series J Preferred Shares are convertible into Common Stock and therefore, no reserves have been created. Shares of Phantom Stock described above and in Note 8. Commitments and Contingencies-Phantom Stock, are not convertible into Common Stock and therefore, no reserves were established for such awards.

5000000

0.001

37500

25001

1376

3500

0.08

0.001

100.00

0.08

0.02

0.0015

15000000

0.08

700

70000

891

709

2791

15000

0.08

0.001

100.00

0.08

0.006

20000000

0.08

570000

5700

9870

5799

9201

3485924 3504424

2000000000

0.001

220728647

56039999

39144372

642219502

31019

25500000

49800000

20361976 39144372

23881

65753

747

1000

67500

45000000

0.0015

<p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-IENE_zms9UHtgo3Uj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of warrant activity for the six-months ended June 30, 2023 is presented below. Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Number of Shares</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Weighted Average Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Weighted Average Remaining Contractual Life (in Years)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 55%">Warrants outstanding and exercisable at December 31, 2022</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20230630_zMZw3Q4hP7Z6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares Warrants, outstanding, Beginning balance">419,683,183</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iS_c20230101__20230630_z4IFuAp4Pqfl" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">0.0074</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_z4XkNTLsdecf" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">3.28</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20230630_z18bbIM8xi8g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares. Warrants Exercised">(49,800,000</td> <td style="font: 10pt Times New Roman, Times, Serif">)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssuedExercised_c20230101__20230630_z8GTWWulxtV3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Exercised">0.0015</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">Issued</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20230630_z4vABa4IrXNk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Issued">83,333,333</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued_c20230101__20230630_z9zYUxZ92sb7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Issued">0.0015</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualIssued_dtY_c20230101__20230630_z0gmXXaAlmKg" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">4.90 </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Expired</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpired_iN_di_c20230101__20230630_zOA2OgPNbeic" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired">(23,881</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired_c20230101__20230630_z5cjtE0ZC3fe" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants Expired">-</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Warrants outstanding and exercisable at June 30, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20230630_zNnQH0orWST5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares Warrants, outstanding, Ending balance">453,192,635</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iE_c20230101__20230630_zvgJ1aokkG81" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">0.0060</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20230630_zEqA93eMQ6jk" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">3.27</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> A summary of warrant activity for the six-months ended June 30, 2022 is presented below. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%">Warrants outstanding at December 31, 2021</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20220630_zXKLgjEozvi5" style="width: 12%; text-align: right" title="Number of Shares, Warrants outstanding, Beginning balance">59,420,298</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iS_c20220101__20220630_zhKb4SpuxHZ3" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Beginning balance">0.0718</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_zhF0Bxk9Ccz5" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">3.3300</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issued as a result of most favored nation provisions</td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20220630_zdnfxirX2iTj" style="text-align: right" title="Number of Shares, Warrants Issued">36,102,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePriceIssued_c20220101__20220630_zEILCTjVbffi" style="text-align: right" title="Weighted Average Exercise Price, Warrants Issued">0.0100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualIssued_dtY_c20220101__20220630_zUniO4Z4Zj6b" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">4.2976</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20220101__20220630_zZcmKOXFpKP8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Expired">(2,212,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePriceExpired_c20220101__20220630_z7MskphIh9Sf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Warrants Expired">0.0160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable at June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20220101__20220630_zNWPToArn8Z5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants outstanding, Ending balance">93,310,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsWeightedAverageExercisePrice_iE_c20220101__20220630_z2rXGjvMfsi9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Warrants outstanding, Ending balance">0.0472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnQgQWN0aXZpdHkgKERldGFpbHMpAA__" id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220630_zG2XoLRi9Cg9" title="Weighted Average Remaining Contractual Life, Warrants Outstanding">2.5557</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

419683183

0.0074 P3Y3M10D

49800000

0.0015

83333333

0.0015 P4Y10M24D -23881

453192635

0.0060 P3Y3M7D <p id="xdx_898_ecustom--ScheduleOfExercisePricesOfCommonStockWarrantsOutstandingAndExercisableTableTextBlock_gL3SOEPOCSWOA-VR_z50DSgUYoXVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2023: Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Warrants Outstanding and Exercisable (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Dates</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztPFh43waUGj" style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: right" title="Warrants, Exercise Price">0.0015</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbtKIjZEGlq8" style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">427,415,641</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zCY4pBx2LKzi">September 30, 2023-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zsf02WbSUa7f">May 22, 2028</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z37J9lJ9Utpf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0389</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaRTwq7CS8d9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">208,227</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztKKUoxwzfLh">May 10, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGZLWh36Sgij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0470</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zha261onpcYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">172,341</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDL90CCuml7f">May 3, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPQF9d9yQThd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0700</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhAaeevzEhN8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">25,377,426</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOPmHYYQUH42">September 30, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">$</td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyRaYBuyJgXj" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Warrants, Exercise Price">15.0000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZuXhDPBDtD5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">19,000</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeSixMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8ZnEL7MWof8">December 30, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztuxXf3JKfZd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding and Exercisable (Shares)">453,192,635</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table> The exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Warrants Outstanding (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Warrants Exercisable (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zg2T20D7h1Gg" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrants, Exercise Price">0.010</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWubTkxPOuvj" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrants, Outstanding (Shares)">67,405,073</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLrIaFwqlHyf" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Warrants, Exercisable (Shares)">67,405,073</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zlOEzAHGX933" title="Expiration Date">September 30, 2023-<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5RZrSZn4Ldk" title="Expiration Date">April 14, 2027 </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRui7OwNEO4e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.0389</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1iZ4miovXn3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">208,227</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaHFMr2QEp96" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">208,227</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGACEUg7uJKk" title="Expiration Date">May 10, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6GNgvJPhmD6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.047</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwp58Z0wCFok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">172,341</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMjkFZg4advh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">172,341</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHGvHg987Zf4" title="Expiration Date">May 3, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8qca5ShjxI9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercise Price">0.070</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZBtkasNSbI5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">25,377,426</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5hbVFxeGSA9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">25,377,426</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ4tC3UMwl3a" title="Expiration Date">September 30, 2023</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zTbhoL4cEVqi" title="Warrants, Exercise Price">11.00 -<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z8kgp6YDODO" title="Warrants, Exercise Price">15.750</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYIXeyPYWOgd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">147,531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5jcLfhst5Pb" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">147,531</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zHiyuzWXEnG2" title="Expiration Date">September 29, 2022-<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zDT60o8Afrj" title="Expiration Date">December 30, 2023</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeov0aEttrt" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Outstanding (Shares)">93,310,598</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEV4ZXJjaXNlIFByaWNlcyBvZiBDb21tb24gU3RvY2sgV2FycmFudHMgT3V0c3RhbmRpbmcgYW5kIEV4ZXJjaXNhYmxlIChEZXRhaWxzKQA_" id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iI_pid_c20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3SZRegDZ0e8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants, Exercisable (Shares)">93,310,598</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td></tr> </table>

0.0015

427415641

2023-09-30

2028-05-22

0.0389

208227

2026-05-10

0.0470

172341

2026-05-03

0.0700

25377426

2023-09-30

15.0000

19000

2023-12-30

453192635

0.0015

427415641

59420298

0.0718 P3Y3M29D

36102800

0.0100 P4Y3M17D

2212500

0.0160

93310598

0.0472 P2Y6M20D

0.010

67405073

2023-09-30

2027-04-14

0.0389

208227

2026-05-10

0.047

172341

2026-05-03

0.070

25377426

2023-09-30

11.00

15.750

147531

2022-09-29

2023-12-30

93310598

0.0038

6325

306000000

13701149

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zfrJVxEr3KLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of stock option activity for the six-months ended June 30, 2023 is presented below. Summary of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life (in Years)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%">Options outstanding at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230630_zC5ptbxO2I39" style="width: 12%; text-align: right" title="Number of Shares, Options outstanding, Beginning balance">9,199,356</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230630_zWnNH5V2w5vh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Options outstanding, Beginning balance">0.592</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z3NmtF0xdKEf" title="Weighted Average Remaining Contractual Life, Options outstanding">3.74</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230630_zCvZNhotovFi" style="text-align: right" title="Number of Shares, Options Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zwrORowl0yG2" style="text-align: right" title="Weighted Average Exercise Price, Options Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230630_zP5Tt8aVgtfl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Options Expired">(31,039</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230630_zOyabDPo2448" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Options Expired">11.200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Options outstanding and exercisable at June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230630_z908LZbhzU31" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Options outstanding, Ending balance">9,168,317</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20230630_zse59s7sJgY1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Options outstanding, Ending balance">0.556</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230630_zc9VEM2fMrn" title="Weighted Average Remaining Contractual Life, Options outstanding">2.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

9199356

0.592

P3Y8M26D

31039

11.200

9168317

0.556

P2Y9M

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_ziRZbP3ZA2q" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2023: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Options Outstanding (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Options Exercisable (Shares)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zCqv0n4jbLwc" title="Options Exercise Price">0.0190</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyiMhFBtaxj1" title="Options Outstanding (Shares)">2,194,444</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zYSYj3i7WDr8" title="Options Exercisable (Shares)">2,194,444</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 43%; text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_ziVhsNGM6Wn3" title="Options, Expiration Date">December 31, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4aebFeNINwk" title="Options Exercise Price">0.0540</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z88Z8dXDhtRi" title="Options Outstanding (Shares)">1,700,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z4moBzvXbFDe" title="Options Exercisable (Shares)">1,700,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z5Ucx1KxIKmf" title="Options, Expiration Date">September 30, 2025</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zf80XwOfan1" title="Options Exercise Price">0.072</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zYMNlXR2Re42" title="Options Outstanding (Shares)">5,050,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zuKAN56nEgSc" title="Options Exercisable (Shares)">5,050,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zaDz77utbtEb" title="Options, Expiration Date">July 31, 2025</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MinimumMember_z5espdr3Iwod" title="Options Exercise Price">7.00-$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MaximumMember_zHKSg0sqEKq4" title="Options Exercise Price">159.25</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zOf5FMkOMXQ3" title="Options Outstanding (Shares)">223,873</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zNtxHhbVPebd" title="Options Exercisable (Shares)">223,873</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MinimumMember_zivqDlNTE5lh" title="Options, Expiration Date">November 21, 2023 - <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20230630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember__srt--RangeAxis__srt--MaximumMember_zssYZuhJzmy6" title="Options, Expiration Date">December 9, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,168,317</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9,168,317</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"> </td></tr> </table>

0.0190

2194444

2026-12-31

0.0540

1700000

2025-09-30

0.072

5050000

2025-07-31

7.00

159.25

223873

2023-11-21

2027-12-09

9168317

0.0015

2000000000

0.001

220728647

9168317

6325

13701149

660982775

453192635

1114175410

7. Related Party Transactions Dr. Arnold S. Lippa and Jeff E. Margolis, officers and directors of RespireRx since March 22, 2013, have indirect ownership and managing membership interests in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis is also an officer of Aurora. Aurora, was a boutique investment banking firm specializing in the life sciences sector that ceased its securities related activities in April 2021 and withdrew its membership with FINRA and its registration with the SEC in July 2021. Although Aurora has not provided services to RespireRx during the six-months ended June 30, 2023 or the fiscal year ended December 31, 2022, Aurora had previously provided services to RespireRx and there remains $96,000 owed to Aurora by RespireRx which amount is included in accounts payable and accrued expenses as June 30, 2023. A description of advances and notes payable to officers and affiliates is provided at Note 4. Notes Payable.

96000

8. Commitments and Contingencies Phantom Stock The features and terms of the Phantom Stock are delineated in Phantom Stock Award Agreements (“Phantom Stock Award Agreements”) which describe that the shares of Phantom Stock that were awarded are non-forfeitable but unvested on the award date which was June 7, 2023 and vest as to the economic value of 50% of the shares of Phantom Stock awarded on the first event payment date (“First Event Payment Date”) and as to the economic value of 50% of the shares of Phantom Stock awarded on the second event payment date (“Second Event Payment Date”). The Phantom Stock Award Agreements terminate on the earlier of the payment to the participant (“Participant”) as a result of the second event or the 15th anniversary of the Phantom Stock Award Agreement. Shares of Phantom Stock are not convertible, exercisable or exchangeable into RespireRx’s Common Stock. Upon the occurrence of a payment Event (“Payment Event”), RespireRx will incur a liability to each Participant that is to be remitted as a cash payment (“Payment”), subject to certain limitations as described below, equal to: (x) the number of vested shares of Phantom Stock held by such Participant, multiplied by (y) the fair market value which on any given day is the value of one share of Common Stock. The Payment, subject to any limitations, shall be made within thirty (30) days after receipt of funds by RespireRx as a result of the Payment Event, and all of such Participant’s shares of Phantom stock that vested as a result of the Payment Date Event shall terminate and be cancelled upon the payment, and the Participant shall have no further rights in respect of that portion of Participant’s shares of Phantom Stock other than rights to receive any unpaid portion of the Payment that was limited by any limitations described below. Any Payment due to a Participant is subject to the execution and non-revocation of general release of claims, in a form provided by RespireRx, and continuous compliance with any restrictive covenant agreement, confidentiality agreement or other agreement entered into between the Participant and RespireRx or its subsidiaries and affiliates. A Payment Event is a monetization event with an unrelated, unaffiliated third party, such as a sale of all or substantially all of an asset, the entering into a joint venture, license or sublicense or a similar transaction structure, that is not an equity or similar or debt investment in RespireRx or a subsidiary unless such equity or similar investment results in a unrelated, unaffiliated third party or group of parties acting together, resulting in such party or parties owning more than a 50% voting interest in RespireRx or a subsidiary and resulting in payments aggregating at least $25,000,000 within a twelve month period to RespireRx. The Payment Event Date, as defined in the Phantom Stock Award Agreement is the first date within twelve months of receipt by RespireRx of cash resulting from a Payment Event, on which RespireRx has received, in the aggregate, at least $25,000,000. The First Payment Event Date shall occur when the first Payment Event has achieved a Payment Event Date at which time a payment is due to the Participant. Similarly, the Second Payment Event Date occurs when the second Payment Event has reached a Payment Event Date at which time a payment is due to the Participant. If two or more of the Company’s assets or platforms or subsidiaries are the subject of a single transaction or series of related transactions, such transactions or series of transactions shall be deemed to represent two Payment Events and the payments to the Company within a twelve-month period as described above would be required to aggregate at least $50,000,000. If the calculation of the payment based on the definition of Fair Market Value, exceeds 50% the amount of cash received by RespireRx with respect to a Payment Event, an initial payment shall be limited to 50% of the cash received by RespireRx with respect to the Payment Event and the unpaid balance shall be carried as a liability due to the Participant to be added to the payment amount of the Second Payment Event, subject to the same limitation. Any remaining liability resulting from the payment amount limitation described in this section after the Second Payment Event shall be reduced to that amount agreed in good faith by the Participant and RespireRx and if no amount can be agreed within ninety (90) days, shall be determined by mediation. Other than adjustments for stock splits, reverse stock splits, stock dividends and similar recapitalizations, the Phantom Stock Award Agreements do not provide for distributions or anti-dilution protections. Nothing contained in the Phantom Stock Award Agreements or RespireRx’s 2014 Equity Plan shall prevent RespireRx from adopting or continuing in effect other compensation arrangements. Jeff Margolis, and Arnold Lippa, each an officer and a director of RespireRx received awards of 120,000,000 and 70,000,000 shares of Phantom Stock, respectively. Our independent director, Joseph R. Siegelbaum was awarded 20,000,000 shares of Phantom Stock. The remaining 96,000,000 of shares of Phantom Stock awarded were awarded to five vendors, consultants, advisors or their designees, one of which is an affiliate. A total of 306,000,000 shares of Phantom Stock were awarded on June 7, 2023. Jeff Margolis and Arnold Lippa immediately transferred all of their shares of Phantom Stock to family trusts in accordance with the terms of the 2014 Plan. The value of the Phantom Stock Awards cannot be determined at this time and can only be estimated or determined upon the occurrence of a Payment Event. Therefore, no amount has been recorded as a commitment or contingency. When or if a Payment Event occurs, an amount will be estimable or determinable and such amount will be recorded as a change in an estimate. Pending or Threatened Legal Action and Claims The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed consolidated financial statements as of June 30, 2023, consolidated financial statements as of December 31, 2022 and condensed consolidated financial statements as of June 30, 2022 with respect to such matters. See Note 5. Settlement and Payment Agreements for additional items and details. Significant Agreements and Contracts Consulting Agreements Richard Purcell, RespireRx’s Senior Vice President of Research and Development since October 15, 2014, has provided his services to RespireRx on an at will and month-to-month basis. Since agreeing to a payment and settlement agreement, RespireRx has contracted for his services on a prepaid hourly basis at a rate of $<span id="xdx_900_ecustom--PaymentsForFeesPerHour_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--RichardPurcellMember__us-gaap--AwardTypeAxis__custom--DNAHealthlinkIncMember_zvibiFFLiCi9" title="Service fee per hour">250 per hour, through his consulting firm, DNA Healthlink, Inc. See Note 5. Payment and Settlement Agreements for a description of the current payment terms. During the six-month period ended June 30, 2023 and the year ended December 31, 2022, Mr. Purcell did not provide any services to RespireRx. The Company anticipates that Mr. Purcell will provide services to the Company during the fiscal year ended December 31, 2023. RespireRx entered into a consulting contract with David Dickason effective September 15, 2020 pursuant to which Mr. Dickason was appointed to and serves as RespireRx’s Senior Vice President of Pre-Clinical Product Development on an at-will basis at the rate of $250 per hour. During the six-month periods ended June 30, 2023 and 2022, Mr. Dickason did not provide any services to RespireRx. Employment Agreements Effective on May 6, 2020, Timothy Jones was appointed as RespireRx’s President and Chief Executive Officer and entered into an employment agreement as of that date. Effective January 31 2022, Mr. Jones resigned as RespireRx’s President and Chief Executive Officer as well as a member of RespireRx’s Board of Directors pursuant to an Employment Agreement Termination and Separation Agreement dated February 8, 2022. See Note 5. Payment and Settlement Agreements. Effective January 31, 2022, Dr. Lippa was appointed as RespireRx’s Interim President and Interim Chief Executive Officer (“CEO”). Dr. Lippa continues to serve as RespireRx’s Executive Chairman and as a member of the Board of Directors as well as the Company’s Chief Scientific Officer (“CSO”). Effective January 11, 2023, Dr. Lippa was appointed as ResolutionRx’s Co-CEO and CSO and is a director of ResolutionRx. Jeff E. Margolis currently serves as RespireRx’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary. Mr. Margolis also serves on RespireRx’s Board of Directors. Effective January 11, 2023, Mr. Margolis was appointed as ResolutionRx’s Co-CEO and Senior Financial Officer and is a director of ResolutionRx. <p id="xdx_896_ecustom--SummaryOfCurrentCashCommitmentsInEmploymentAgreementsTableTextBlock_zfnHNP2wyKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below summarized the current cash commitments to Dr. Lippa and Mr. Margolis through the next September 30th renewal date. Summary of Current Cash Commitments in Employee Agreements <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="10" style="text-align: center">Contract year ending</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Three months</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Base</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Salary</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Benefits</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left">Arnold S. Lippa</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SalariesWagesAndOfficersCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--DrArnoldSLippaMember_zH0Y5zjx1uZg" style="width: 12%; text-align: right" title="Base Salary">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--DrArnoldSLippaMember_zqsLc74sJkm" style="width: 12%; text-align: right" title="Benefits">9,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LaborAndRelatedExpense_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--DrArnoldSLippaMember_zLVreHBLme8d" style="width: 12%; text-align: right" title="Total">84,900</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Jeff E. Margolis</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SalariesWagesAndOfficersCompensation_pdp0_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--MrMargolisMember_zsLp9CPT5RNe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Base Salary">75,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--MrMargolisMember_ziCfrzjeKKDc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Benefits">5,400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--LaborAndRelatedExpense_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--MrMargolisMember_zRqoQIMS43Dj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">80,400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--SalariesWagesAndOfficersCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zFWm7he3tVac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Base Salary">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z6A54LgqYwDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Benefits">15,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--LaborAndRelatedExpense_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zUE1kpTLSie6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">165,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Under certain circumstances base salaries may be contractually increased or the executives may become eligible for additional benefits and base salaries may be increased at the discretion of the Board of Directors. All executives are eligible for stock and stock option and similar grants at the discretion of the Board or Directors. The payment of certain amounts reflected in the table above have been voluntarily deferred indefinitely and payments against accrued compensation may be made based upon RespireRx’s ability to make such payments. UWMRF Patent License Agreement On August 1, 2020, RespireRx exercised its option pursuant to its option agreement dated March 2, 2020, between RespireRx and UWM Research Foundation, an affiliate of the University of Wisconsin-Milwaukee (“UWMRF”). Upon exercise, RespireRx and UWMRF executed the UWMRF Patent License Agreement effective August 1, 2020 pursuant to which RespireRx licensed the identified intellectual property. Under the UWMRF Patent License Agreement, RespireRx has an exclusive license to commercialize GABAkine products based on UWMRF’s rights in certain patents and patent applications, and a non-exclusive license to commercialize products based on UWMRF’s rights in certain technology that is not the subject of the patents or patent applications. UWMRF maintains the right to use, and, upon the approval of RespireRx, to license, these patent and technology rights for any non-commercial purpose, including research and education. The UWMRF Patent License Agreement expires upon the later of the expiration of RespireRx’s payment obligations to UWMRF or the expiration of the last remaining licensed patent granted thereunder, subject to early termination upon the occurrence of certain events. The License Agreement also contains a standard indemnification provision in favor of UWMRF and confidentiality provisions obligating both parties. Under the UWMRF Patent License Agreement, in consideration for the licenses granted, RespireRx will pay to UWMRF the following: (i) patent filing and prosecution costs incurred by UWMRF prior to the effective date, paid in yearly installments over three years from the Effective Date; (ii) annual maintenance fees, beginning on the second anniversary of the Effective Date, which annual maintenance fees terminate upon RespireRx’s payment of royalties pursuant to clause (iv) below; (iii) milestone payments, paid upon the occurrence of certain dosing events of patients during clinical trials and certain approvals by the FDA; and (iv) royalties on net sales of products developed with the licenses, subject to minimum annual payments and to royalty rate adjustments based on whether separate royalty payments by RespireRx yield an aggregate rate beyond a stated threshold. RespireRx will pay to UWMRF certain percentages of revenues generated from sublicenses of the licenses provided under the UWMRF Patent License Agreement by RespireRx to third parties. Certain payments under the UWMRF Patent License Agreement have not been paid by RespireRx. RespireRx is in regular discussions with UWMRF regarding when RespireRx may be able to commence making payments. RespireRx has not received a notification of default either during or before the six-month period ended June 30, 2023 or in any subsequent periods. All amounts due under the UWMRF Patent License Agreement are reflected in the Company’s condensed consolidated financial statements as of June 30, 2023 and December 31, 2022 in accounts payable and accrued expenses. University of Wisconsin-Milwaukee Outreach Services Agreement On July 12, 2021, RespireRx and the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Milwaukee (“UWM”) entered into an Outreach Services Agreement pursuant to which UWM agreed to provide, among other molecules, multiple milligram to gram quantities of KRM-II-81 (GABAkine) and RespireRx agreed to pay UWM an annual sum of $75,000 payable in three installments of $<span id="xdx_90C_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_pp0p0_c20210712__us-gaap--AwardTypeAxis__custom--ThreeInstallmentsMember_zHiCoS1Z9Bek" title="Purchase commitment, remaining minimum amount committed">25,000 each beginning October 12, 2021, which amount was timely paid, and on a quarterly basis thereafter. The payments that were due on January 12, 2022 and April 12, 2022 have not yet been paid. The agreement terminated on June 30, 2022. Amounts due totaling $50,000 on January 12, 2022 and April 12, 2022 are recorded in accounts payable as of June 30, 2023 and December 31, 2022. Payment of $35,185 comprised of $30,185, which is 50% of the patent fees identified in the license, and $5,000 annual maintenance fee were due but unpaid at August 1, 2023. University of Illinois 2014 Exclusive License Agreement On June 27, 2014, RespireRx entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including: (i) the payment by RespireRx of a $25,000 licensing fee, (ii) the payment by RespireRx of outstanding patent costs aggregating $15,840, and (iii) the assignment to the University of Illinois of rights RespireRx held in certain patent applications, all of which conditions were fulfilled. The 2014 License Agreement was amended on July 25, 2017 and effective December 15, 2022, the first amendment was to extend certain timeframes and the second amendment represented an extensive set of modifications (“2nd Amendment”). The 2014 License Agreement granted RespireRx (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea. Among other things, the 2nd Amendment redefined the term “Product” primarily to include in the definition, any product or process that would be enforceable under the licensed patent rights after the patent rights have expired. In addition, new definitions were added for “Deferred Compensation Annual Net Sales Payments” and “Deferred Compensation Minimum Payment(s),” both of which only become due and payable after the expiration of the patent rights and shall not be due and payable while any of the patent rights have not yet expired. These deferred compensation arrangements were in consideration for deferment of certain financial obligations. The deferred payments are due for eight years from the first commercial sale of a regulatory approved product but after the patent rights have expired. The 2nd Amendment also modified the term to the period of time from the effective date until the later of the date: (a) of the last to lapse, expire or terminate of the patent rights or (b) when the licensee (RespireRx) provides notice that the use of technical information as defined in the 2014 License Agreement as amended has ceased or (c) of the expiration of the last form of market exclusivity or (d) of the last date in which the Licensee (RespireRx) owes payments to the University. The 2nd Amendment amended and clarified Schedule 2 to the 2014 License Agreement, as amended by among other things, by (i) including a <span id="xdx_902_ecustom--PercentageOfRoyaltyOnNetSale_pid_dp_uPure_c20140625__20140627__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zImTS9A8sUo6" title="Percentage of royalty on net sale">4% royalty on Net Sales by the Licensee or sublicensee as Deferred Compensation Annual License Payments The 2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015. In addition, the 2014 License Agreement provides for various royalty payments, including a royalty on net sales of <span id="xdx_90D_ecustom--PercentageOfRoyaltyOnNetSale_pid_dp_uPure_c20150630__20150630__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zWzHArAzNA47" title="Percentage of royalty on net sale">4%, payment on sub-licensee revenues of <span id="xdx_909_ecustom--PercentageOfPaymentOnSubLicenseeRevenue_pid_dp_uPure_c20150630__20150630__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zPQLhQakXLw4">12.5%, and a minimum annual royalty beginning in 2015 of $100,000, which is due and payable on December 31 of each year beginning on December 31, 2015. The minimum annual royalty obligation of $<span id="xdx_905_eus-gaap--RoyaltyExpense_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zbqiNKqJ9A1j" title="Royalty expense">100,000 due on December 31, 2021, was extended to May 31, 2022 and then further extended to an indefinite future date while discussions to amend the obligation are taking place. The minimum annual royalty obligation due on December 31, 2021 has not yet been paid. What was the $<span id="xdx_906_ecustom--MinimumAnnualRoyaltyObligation_c20211229__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndFourteenLicenseAgreementMember_zGESk9rg2Mg4" title="Minimum annual royalty obligation">100,000 annual minimum that existed from inception through December 31, 2020 was eliminated and therefore the amounts previously recorded in accounts payable and accrued expenses, were reduced to $0. The annual minimum amount due the first year with a market approval from the US FDA (United States Food and Drug Administration) or a foreign equivalent and every year thereafter until the first commercial sale of $350,000 of a product replaced two similarly timed payments of $<span id="xdx_90E_ecustom--ResearchAndDevelopmentDuringPeriod_c20230101__20230630__us-gaap--OtherCommitmentsAxis__custom--FirstTimedPaymentsMember_zsdLY1QCV3nh" title="Research and Development during period">150,000 and $<span id="xdx_909_ecustom--ResearchAndDevelopmentDuringPeriod_c20230101__20230630__us-gaap--OtherCommitmentsAxis__custom--SecondTimedPaymentsMember_zXYzpeeuhEpf" title="Research and Development during period">200,000. The first year with a commercial sale of a product and every year thereafter is now $400,000 whereas it was previously $<span id="xdx_908_ecustom--CommercialProductSale_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndFourteenLicenseAgreementMember__us-gaap--OtherCommitmentsAxis__custom--AfterFirstYearMember_zFkughJR3wj" title="Commercial Product Sale">250,000 after the first year of commercial sale. One time milestone payments have been changed to read as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_906_eus-gaap--PaymentsForRent_c20230101__20230630__srt--StatementScenarioAxis__custom--DueWithinFiveDaysAfterDosingOfFirstPatientPhaseTwoHumanClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zKrrglDcg2Sa" title="Payments for rent">10,000 due within 5 days after dosing of the first patient with a product in a Phase II human clinical study anywhere in the world.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_907_eus-gaap--PaymentsForRent_c20230101__20230630__srt--StatementScenarioAxis__custom--DueWithinFiveDaysAfterDosingOfFirstPatientPhaseThreeHumanClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zqqecGnD6gSg" title="Payments for rent">150,000 due within 5 days after dosing of the first patient with a product in a Phase III human clinical study anywhere in the world.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(iii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_90E_eus-gaap--PaymentsForRent_c20230101__20230630__srt--StatementScenarioAxis__custom--DueWithinFiveDaysAfterDosingOfFirstPatientPhaseThreeHumanClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementThreeMember_z5ph7EiEHaf3" title="Payments for rent">350,000 due within 5 days after the earlier date of the following (a) enrolling 80% of the patients with a product in the Phase III human clinical study anywhere in the world, (b) one year after the initiation of the Phase III human clinical study anywhere in the world, or (c) termination of the Phase III human clinical study anywhere in the world.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(iv)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20230630__srt--StatementScenarioAxis__custom--DueWithinFiveDaysAfterFirstNewDrugApplicationFilingMember__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zCpX5q3itV9a" title="Payments for rent">500,000 due within 5 days after the first NDA (New Drug Application) filed with the US FDA or any other foreign equivalent regulatory agency for a product anywhere in the world.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(v)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_90A_eus-gaap--PaymentsForRent_c20230101__20230630__srt--StatementScenarioAxis__custom--DueWithinTwelveMonthsOfFirstCommercialSaleMember__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zn5Ln1P180xe" title="Payments for rent">1,000,000 due within twelve (12) months after the first commercial sale of a product anywhere in the world.</td></tr> </table> There are reporting requirements by the Licensee to the University. Royalty stacking provisions remained unchanged in the 2nd Amendment. The concept of reduced royalties upon expiration of the patent rights, but while technical information was being used, was eliminated with the 2nd Amendment. During the six-months ended June, 2023 and 2022, the Company recorded charges to operations of $<span id="xdx_90D_ecustom--ChargeToOperationsWithRoyaltyObligation_c20230101__20230630__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zQvoTxL2Kgce">0 and $<span id="xdx_90F_ecustom--ChargeToOperationsWithRoyaltyObligation_c20220101__20220630__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zkfHlASJNi63">50,000, respectively representing, in 2022, the pre-amendment annual minimum royalty, which was included in research and development expenses in the Company’s condensed consolidated statement of operations. The $<span id="xdx_903_ecustom--ChargeToOperationsWithRoyaltyObligation_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_zMez0l4dA1ai">100,000 from the fiscal year ended December 31, 2021 was reversed as a result of the effectiveness of the 2nd Amendment as of December 15, 2022 and the estimate for the fiscal year ended December 31, 2022 was $<span id="xdx_90B_ecustom--ChargeToOperationsWithRoyaltyObligation_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--UniversityOfIllinoisTwoThousandFourteenExclusiveLicenseAgreementMember_znMHGF4iB0n5">0. Noramco Inc. - Dronabinol Development and Supply Agreement On September 4, 2018, RespireRx entered into a dronabinol Development and Supply Agreement with Noramco Inc., one of the world’s major dronabinol manufacturers, which Noramco subsequently assigned to its subsidiary, Purisys LLC (the “Purisys Agreement”). Under the terms of the Purisys Agreement, Purisys agreed to (i) provide all of the active pharmaceutical ingredient (“API”) estimated to be needed for the clinical development process for both the first- and second-generation products (each a “Product” and collectively, the “Products”), three validation batches for New Drug Application (“NDA”) filing(s) and adequate supply for the initial inventory stocking for the wholesale and retail channels, subject to certain limitations, (ii) maintain or file valid drug master files (“DMFs”) with the FDA or any other regulatory authority and provide RespireRx with access or a right of reference letter entitling RespireRx to make continuing reference to the DMFs during the term of the agreement in connection with any regulatory filings made with the FDA by RespireRx, (iii) participate on a development committee, and (iv) make available its regulatory consultants, collaborate with any regulatory consulting firms engaged by RespireRx and participate in all FDA or Drug Enforcement Agency (“DEA”) meetings as appropriate and as related to the API. We now refer to the second-generation product as our proprietary formulation or proprietary product and have de-emphasized the first-generation product. In consideration for these supplies and services, RespireRx has agreed to purchase exclusively from Noramco during the commercialization phase all API for its Products as defined in the Development and Supply Agreement at a pre-determined price subject to certain producer price adjustments and agreed to Noramco’s participation in the economic success of the commercialized Product or Products up to the earlier of the achievement of a maximum dollar amount or the expiration of a period of time. There was no activity during the six-month periods ended June 30, 2023 or 2022 with respect to the Purisys Agreement. During June 2023, the Company engaged in discussions with Purisys with the intent of amending the Purisys Agreement or cancelling the Purisys Agreement and establishing a new agreement. The anticipated new formulations and the formation of ResolutionRx in Australia are the primary reasons for participating in such discussions. Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of June 30, 2023, aggregating $255,485. License agreement amounts included in the 2023 column represent amounts contractually due from July 1, 2023 through December 31, 2023 (six months) and in each of the subsequent years, represents the full year. Employment agreement amounts included in the 2023 column represent amounts contractually due from July 1, 2023 through September 30, 2023 (three months) when such contracts expire unless extended pursuant to the terms of the contracts. <p id="xdx_891_ecustom--SummaryOfPrincipalCashObligationsAndCommitmentsTableTextBlock_zMic7x4BBIK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Summary of Principal Cash Obligations and Commitments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Payments Due By Year</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2025</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2026</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2027</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">License agreements</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractualObligation_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zsEzElwP5hjb" style="width: 6%; text-align: right" title="Total">90,185</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zLogLZxmAw4i" style="width: 6%; text-align: right" title="2023">35,185</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_z5pXUubH2OR6" style="width: 6%; text-align: right" title="2024">10,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractualObligationDueInSecondYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zvnSPwHwLJe2" style="width: 6%; text-align: right" title="2025">15,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ContractualObligationDueInThirdYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_z4R1OSbw2tf1" style="width: 6%; text-align: right" title="2026">15,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractualObligationDueInFourthYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zILxRt3ekV8d" style="width: 6%; text-align: right" title="2027">15,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_F49_zNAPzJbwSyib" style="text-align: left; padding-bottom: 1.5pt">Employment agreements (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ContractualObligation_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zjhXMg0B1Bs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">165,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zu4dRGRA5p0j" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023">165,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_z01sb4lzrubc" style="border-bottom: Black 1.5pt solid; text-align: right" title="2024">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractualObligationDueInSecondYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zTeaUTI1ku99" style="border-bottom: Black 1.5pt solid; text-align: right" title="2025">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractualObligationDueInThirdYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zVTb8ELF6lYc" style="border-bottom: Black 1.5pt solid; text-align: right" title="2026">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ContractualObligationDueInFourthYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zbLWvKr9uS8k" style="border-bottom: Black 1.5pt solid; text-align: right" title="2027">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractualObligation_iI_pp0p0_c20230630_zZufEkYYavyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">255,485</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pp0p0_c20230630_zvKWb6D1bj2i" style="border-bottom: Black 2.5pt double; text-align: right" title="2023">200,485</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pp0p0_c20230630_zbAriYEoCUH" style="border-bottom: Black 2.5pt double; text-align: right" title="2024">10,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractualObligationDueInSecondYear_iI_pp0p0_c20230630_zNY59PpgAbkk" style="border-bottom: Black 2.5pt double; text-align: right" title="2025">15,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractualObligationDueInThirdYear_iI_pp0p0_c20230630_zkigJKiID9oc" style="border-bottom: Black 2.5pt double; text-align: right" title="2026">15,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ContractualObligationDueInFourthYear_iI_pp0p0_c20230630_z17mnnHjiYc6" style="border-bottom: Black 2.5pt double; text-align: right" title="2027">15,0000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements.”</td></tr> </table>

The features and terms of the Phantom Stock are delineated in Phantom Stock Award Agreements (“Phantom Stock Award Agreements”) which describe that the shares of Phantom Stock that were awarded are non-forfeitable but unvested on the award date which was June 7, 2023 and vest as to the economic value of 50% of the shares of Phantom Stock awarded on the first event payment date (“First Event Payment Date”) and as to the economic value of 50% of the shares of Phantom Stock awarded on the second event payment date (“Second Event Payment Date”)

0.50

If the calculation of the payment based on the definition of Fair Market Value, exceeds 50% the amount of cash received by RespireRx with respect to a Payment Event, an initial payment shall be limited to 50% of the cash received by RespireRx with respect to the Payment Event and the unpaid balance shall be carried as a liability due to the Participant to be added to the payment amount of the Second Payment Event, subject to the same limitation.

120000000

70000000

20000000

96000000

306000000

250 250 250 <p id="xdx_896_ecustom--SummaryOfCurrentCashCommitmentsInEmploymentAgreementsTableTextBlock_zfnHNP2wyKs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below summarized the current cash commitments to Dr. Lippa and Mr. Margolis through the next September 30th renewal date. Summary of Current Cash Commitments in Employee Agreements <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="10" style="text-align: center">Contract year ending</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Three months</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center">Base</td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Salary</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Benefits</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%; text-align: left">Arnold S. Lippa</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SalariesWagesAndOfficersCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--DrArnoldSLippaMember_zH0Y5zjx1uZg" style="width: 12%; text-align: right" title="Base Salary">75,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--DrArnoldSLippaMember_zqsLc74sJkm" style="width: 12%; text-align: right" title="Benefits">9,900</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--LaborAndRelatedExpense_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--DrArnoldSLippaMember_zLVreHBLme8d" style="width: 12%; text-align: right" title="Total">84,900</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Jeff E. Margolis</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SalariesWagesAndOfficersCompensation_pdp0_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--MrMargolisMember_zsLp9CPT5RNe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Base Salary">75,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--MrMargolisMember_ziCfrzjeKKDc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Benefits">5,400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--LaborAndRelatedExpense_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember__srt--TitleOfIndividualAxis__custom--MrMargolisMember_zRqoQIMS43Dj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">80,400</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--SalariesWagesAndOfficersCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zFWm7he3tVac" style="border-bottom: Black 1.5pt solid; text-align: right" title="Base Salary">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z6A54LgqYwDi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Benefits">15,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--LaborAndRelatedExpense_c20230401__20230930__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zUE1kpTLSie6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">165,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

75000

9900

84900

75000

5400

80400

150000

15300

165300

75000

25000

50000

35185 30185 0.50 5000 25000 15840 0.04 0.04 0.125

100000

100000 0 350000 150000 200000 400000 250000

10000

150000

350000

500000

1000000

0 50000 100000 0

255485

<p id="xdx_891_ecustom--SummaryOfPrincipalCashObligationsAndCommitmentsTableTextBlock_zMic7x4BBIK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Summary of Principal Cash Obligations and Commitments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center">Payments Due By Year</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2025</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2026</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2027</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">License agreements</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractualObligation_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zsEzElwP5hjb" style="width: 6%; text-align: right" title="Total">90,185</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zLogLZxmAw4i" style="width: 6%; text-align: right" title="2023">35,185</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_z5pXUubH2OR6" style="width: 6%; text-align: right" title="2024">10,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractualObligationDueInSecondYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zvnSPwHwLJe2" style="width: 6%; text-align: right" title="2025">15,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ContractualObligationDueInThirdYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_z4R1OSbw2tf1" style="width: 6%; text-align: right" title="2026">15,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractualObligationDueInFourthYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__us-gaap--LicensingAgreementsMember_zILxRt3ekV8d" style="width: 6%; text-align: right" title="2027">15,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td id="xdx_F49_zNAPzJbwSyib" style="text-align: left; padding-bottom: 1.5pt">Employment agreements (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ContractualObligation_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zjhXMg0B1Bs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">165,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zu4dRGRA5p0j" style="border-bottom: Black 1.5pt solid; text-align: right" title="2023">165,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_z01sb4lzrubc" style="border-bottom: Black 1.5pt solid; text-align: right" title="2024">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractualObligationDueInSecondYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zTeaUTI1ku99" style="border-bottom: Black 1.5pt solid; text-align: right" title="2025">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ContractualObligationDueInThirdYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zVTb8ELF6lYc" style="border-bottom: Black 1.5pt solid; text-align: right" title="2026">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ContractualObligationDueInFourthYear_iI_pp0p0_c20230630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_fKDEp_zbLWvKr9uS8k" style="border-bottom: Black 1.5pt solid; text-align: right" title="2027">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--ContractualObligation_iI_pp0p0_c20230630_zZufEkYYavyf" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">255,485</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_pp0p0_c20230630_zvKWb6D1bj2i" style="border-bottom: Black 2.5pt double; text-align: right" title="2023">200,485</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ContractualObligationDueInNextTwelveMonths_iI_pp0p0_c20230630_zbAriYEoCUH" style="border-bottom: Black 2.5pt double; text-align: right" title="2024">10,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ContractualObligationDueInSecondYear_iI_pp0p0_c20230630_zNY59PpgAbkk" style="border-bottom: Black 2.5pt double; text-align: right" title="2025">15,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ContractualObligationDueInThirdYear_iI_pp0p0_c20230630_zkigJKiID9oc" style="border-bottom: Black 2.5pt double; text-align: right" title="2026">15,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ContractualObligationDueInFourthYear_iI_pp0p0_c20230630_z17mnnHjiYc6" style="border-bottom: Black 2.5pt double; text-align: right" title="2027">15,0000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements.”</td></tr> </table>

90185

35185

10000

15000

165300

255485

200485

10000

15000

15.0000

9. Subsequent Events Entry into License Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx (“Licensor”) and ResolutionRx (“Licensee”), its wholly-owned, unlisted, public Australian subsidiary entered into a License Agreement (“License Agreement”) pursuant to which, RespireRx has licensed to ResolutionRx, the Intellectual Property (“Licensed IP” as defined in the License Agreement) which includes the Patent Rights (“Patent Rights” as defined in the License Agreement). The License (“License”) is an exclusive, worldwide and royalty-free license during the Term to use and exploit the Licensed IP in connection with ResolutionRx’s business and operations, including commercial and non-commercial purposes, with the exception that RespireRx shall have the exclusive right to use the technology described in the Licensed IP for non-cannabinoid products. ResolutionRx shall use its best efforts to commercialize the Licensed IP. The Licensed IP is basically, the intellectual property and patent rights, identified in Schedule A of the License Agreement and associated with the new dronabinol formulation initially to be developed for the treatment of obstructive sleep apnea. The consideration for the License and the related Sublicense (see Sublicense Agreement between RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd and Share Transfer Agreement below) is the issuance of <span id="xdx_900_eus-gaap--SharesIssued_iI_c20230803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ShareTransferAgreementMember_zy3SVErCQ0w8" title="Ordinary shares issued">25,000,000 Ordinary Shares of ResolutionRx to RespireRx plus the payment of US$<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20230803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ShareTransferAgreementMember_zOP1q6s4nvb4" title="Payment">1 to RespireRx. Licensee shall not sublicense any of its rights and/or obligations under the License Agreement without the prior written consent of Licensor, except to contract manufacturers, distributors and other third parties engaged by Licensee pursuant to the normal course of Licensee’s business (the “Sublicensees”) on terms consistent with and not in conflict with this License Agreement, and in no event less protective of Licensor’s rights than those set forth in the License Agreement. Such agreements with Sublicensees shall terminate upon termination of this License Agreement. The Licensor shall be responsible for patent prosecution and maintenance and Licensee shall promptly either pay directly or reimburse Licensor’s costs in each jurisdiction. ResolutionRx as Licensee, at its option may control prosecution and maintenance of the Patent Rights. The License Agreement also addresses how the parties are to deal with interferences, if any. All unpublished information is to be treated confidentially. ResolutionRx acknowledges in the License Agreement, that RespireRx is the owner of all right, title and interest in and to the Licensed IP, including all modifications, enhancements, improvements and other derivative works (“Modifications”). All Modifications are Licensed IP immediately upon their creation. Licensee shall promptly notify Licensor of any actual or potential infringement, counterfeiting, or other unauthorized use of the Licensed IP by any other person or entity of which Licensee becomes aware. Licensor shall have the right, but not obligation, in its sole discretion, to enforce its rights in the Licensed IP, including to bring action with respect to any infringement of the Licensed IP. With respect to the Licensed Patents, the term of the License Agreement shall commence as of the Effective Date, as defined in the License Agreement, and shall be effective until the last of the Licensed Patents, as defined in the License Agreement, expires (the “Patent Term”). With respect to the Licensed IP but excluding the Licensed Patents, the initial term of this License Agreement shall commence as of the Effective Date and shall be effective for a period of two (2) years (the “Initial Term”) and shall automatically be renewed for successive annual terms (each a “Renewal Term”) unless Licensee gives written notice to the Licensor of its intent not to renew at least sixty (60) days prior to the end of the Initial Term or then current Renewal Term, as applicable. Licensee and Licensor have indemnified one another. The License Agreement is governed by and construed in accordance with Delaware Law, without regard to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction). Entry into Sublicense Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx as sublicensor (“Sublicensor”) and ResolutionRx as sublicensee (“Sublicensee”), entered into a Sublicense Agreement (“Sublicense Agreement”) whereby Sublicensor, sublicensed the rights to its Exclusive License Agreement with The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois (“University”), effective June 27, 2014 (the “Original License”) and amended via that certain letter amendment, effective August 2, 2017 (the “Letter Amendment”) and that certain Second Amendment to RespireRx-University of Illinois Exclusive License Agreement, effective December 15, 2022 (the “Second Amendment,” and collectively with the Original License and Letter Amendment, the “Exclusive License” which is the same as the 2014 License Agreement described elsewhere in our condensed consolidated financial statements as of June 30, 2023), pursuant to which the University granted to RespireRx certain rights and licenses. The Exclusive License permits Sublicensor to grant written sublicenses of its rights under the Exclusive License. The consideration for the Sublicense and the related License (see License Agreement between RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd above and Share Transfer Agreement below) is the issuance of <span id="xdx_900_eus-gaap--SharesIssued_iI_c20230803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ShareTransferAgreementMember_zofNcod0icib" title="Ordinary shares issued">25,000,000 Ordinary Shares of ResolutionRx to RespireRx plus the payment of US$<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20230803__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ShareTransferAgreementMember_zl0NKCb1Tt9i" title="Payment">1 to RespireRx. The Sublicense is essentially a direct pass-through of all of the rights and obligations associated with the Exclusive License from RespireRx as Sublicensor to ResolutionRx as Sublicensee. The Sublicense expires upon the termination of the Exclusive License. Entry into Stock Transfer Agreement with ResolutionRx Ltd On August 3, 2023, ResolutionRx as transferor (“Transferor”) and RespireRx as transferee (“Transferee”) entered into a Stock Transfer Agreement (“Stock Transfer Agreement”) whereby the Transferor and Transferee agreed that Transferor which has the authority under its Constitution to issue the 25,000,000 Ordinary Shares that are set out in the Stock Transfer Agreement, transfers absolutely, all title over the Ordinary Shares to the Transferee in consideration of the License Agreement and the Sublicense Agreement. Entry into Master Intercompany Services Agreement with ResolutionRx Ltd On August 3, 2023, RespireRx as the provider of services (“Provider”) and ResolutionRx as the recipient of services (“Recipient”) entered into a Master Intercompany Services Agreement (“MISA”). As of the date of the MISA, ResolutionRx was a wholly-owned Australian unlisted public subsidiary of RespireRx. Provider performs certain support activities in the form of both general and administrative and research and development support in the execution of the business operations of Recipient. The initial term of the MISA is from August 3, 2023 for two years. The MISA automatically renews for successive one-year periods unless Recipient gives written notice to Provider of its intent not to renew at least ninety days prior the end of the initial term or any renewal term. Provider will provide the services as set forth on Schedule A of the MISA on an ongoing basis as well as such further services as Recipient and Provider may specifically agree upon from time to time (the “Services”). As noted on Schedule A, and for clarity, Recipient specifically agrees to remit to Provider for the Services or components (“Components”) of the Services until such time as the Components are no longer required and when such Components are provided by a party in Australia other than Provider, or such Components are no longer subcontracted for by Provider and Provider agrees to no longer provide such Components or Services. The MISA also describes the selection of personnel and subcontracting. Provider will invoice Recipient for the Services to be performed on a quarterly basis (based on the fiscal year of Recipient) with such invoices to be issued, in advance, for Services to be rendered in the quarter following the date of each such invoice. Recipient will pay Provider a fee (“Fee”) as set forth on Schedule B of the MISA, which may be amended by the Parties from time to time. Only those costs and expenses wholly and exclusively or otherwise properly attributed to the provision and coordination of provision of the Services will be included in the calculation of the Fee. Fees are payable in US dollars unless otherwise agreed by the parties. Annually, based on the fiscal year of Recipient, Provider must deliver to Recipient its budget for the costs and expenses it reasonably believes will be incurred in the provision of the Services (“Budget”) which amounts may be increased by written agreement of Recipient and Provider. The Recipient and the Provider have each indemnified one another. The MISA also establishes confidentiality provisions. Post June 30, 2023 Convertible Note Conversions During the period from July 11, 2023 through August 18, 2023, three convertible note holders of notes with substantially similar attributes converted $65,753 of principal, $747 of interest, $1,000 of conversion fees for a total of $67,500, into 45,000,000 shares of Common Stock at a conversion price, in each case, of $0.0015 per share of Common Stock. Patent fees and maintenance fees of $35,185 due to UWMRF at August 1, 2023 were unpaid Payment of $<span id="xdx_90F_eus-gaap--ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_iI_c20230801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zd8fTwH9tpOd" title="Payments to obligation">35,185 comprised of $30,185, which is 50% of the patent fees identified in the license and $5,000 annual maintenance fee were due to UWMRF but unpaid at August 1, 2023.

25000000

65753

747

1000

67500

45000000

0.0015

35185

30185 0.50 5000 These convertible notes were sold to investors in 2014 and 2015 (“Original Convertible Notes) and have a fixed interest rate of 10% per annum and in the case of the one note for which a notice of default has been received, 12%. The Original Convertible Notes have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events and are convertible into an aggregate of 1,560 shares of Common Stock as of June 30, 2023. As of June 30, 2023, principal and accrued interest on the Original Convertible Note that is subject to a default notice totaled $67,443, of which $42,443 was accrued interest. On December 31, 2018 and January 2, 2019, the Company issued convertible notes to a single investor totaling $35,000 of maturity amount with accrued interest of $19,695 as of June 30, 2023. The number of shares of common stock (or preferred stock) into which these notes may convert is not determinable. These fourteen convertible notes were issued between May 17, 2019 and August 22, 2022. They all currently have similar terms including conversion prices that generally are or are likely to be $0.0015 per share of Common Stock. All such notes matured prior to June 30, 2023. The Company has initiated discussions with all note holders regarding maturity date extensions. The Company has not received any notices of default with respect to these notes. Certain notes are accruing interest at the default interest rates even though no notices of default have been received. These notes contain, among other provisions, most favored nation provisions, reserve requirements and default interest rates. The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements.”